

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

(10) International Publication Number
WO 03/066587 A2

(51) International Patent Classification⁷: C07D 211/00 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US03/01079

(22) International Filing Date: 3 February 2003 (03.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/353,183 4 February 2002 (04.02.2002) US
10/351,597 27 January 2003 (27.01.2003) US

(71) Applicant (*for all designated States except US*): CHIRON CORPORATION [US/US]; 4650 Horton Street, Emeryville, CA 94608-2916 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BOYCE, Rustum [IN/US]; 1818 Broadway, #206, San Francisco, CA 94109 (US). CHU, Daniel [US/US]; 3767 Benton Street, Santa Clara, CA 95051 (US). LENTINI, David [US/US]; 1932 California Street, San Francisco, CA 94109 (US).

(74) Agents: COLLIER, Steven, W. et al.; Chiron Corporation, Intellectual Property R338, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066587 A2

(54) Title: NOVEL GUANIDINYL DERIVATIVES

(57) Abstract: A variety of small, guanidino group-containing molecules capable of acting as MC4-R agonists are provided. The compounds have various structures provided herein. The compounds are useful in treating MC4-R mediated diseases and may be formulated into pharmaceutical formulations and compositions.

NOVEL GUANIDINYLYL DERIVATIVES

FIELD OF THE INVENTION

This invention relates to melanocortin-4 receptor (MC4-R) agonists and methods of their preparation. The invention also relates to methods of treating melanocortin-4 receptor-mediated diseases, such as obesity or diabetes, by activating the melanocortin-4 receptor with compounds 5 provided herein.

BACKGROUND OF THE INVENTION

Melanocortins are peptide products resulting from post-translational processing of pro-opiomelanocortin and are known to have a broad array of physiological activities. The natural melanocortins include the different types of melanocyte stimulating hormone (α -MSH, β -MSH, γ -MSH) 10 and ACTH. Of these, α -MSH and ACTH are considered to be the main endogenous melanocortins.

The melanocortins mediate their effects through melanocortin receptors (MC-Rs), a subfamily of G-protein coupled receptors. There are at least five different receptor subtypes (MC1-R to MC5-R). MC1-R mediates 15 pigmentation of the hair and skin. MC2-R mediates the effects of ACTH on steroidogenesis in the adrenal gland. MC3-R and MC4-R are predominantly expressed in the brain. MC5-R is considered to have a role in the exocrine gland system.

The melanocortin-4 receptor (MC4-R) is a seven-20 transmembrane receptor. MC4-R may participate in modulating the flow of visual and sensory information, coordinate aspects of somatomotor control, and/or participate in the modulation of autonomic outflow to the heart. K. G.

-2-

Mountjoy *et al.*, *Science*, 257:1248-125 (1992). Significantly, inactivation of this receptor by gene targeting has resulted in mice that develop a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia. D. Husztrai *et al.*, *Cell*, 88(1): 131-41 (1997). MC4-R has 5 also been implicated in other disease states including erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and sexual behavior disorders. M. E. Hadley and C. Haskell-Luevano, The proopiomelanocortin system, *Ann. N. Y. Acad. Sci.*, 885:1 (1999).

10 Furthermore, observations in connection with endogenous MCx-R antagonists indicate that MC4-R is implicated in endogenous energy regulation. For example, an agouti protein is normally expressed in the skin and is an antagonist of the cutaneous MC receptor involved in pigmentation, MC1-R. M. M. Ollmann *et al.*, *Science*, 278:135-138 (1997). However, 15 overexpression of agouti protein in mice leads to a yellow coat color due to antagonism of MC1-R and increased food intake and body weight due to antagonism of MC4-R. L. L. Kiefer *et al.*, *Biochemistry*, 36: 2084-2090 (1997); D. S. Lu *et al.*, *Nature*, 371:799-802 (1994). Agouti related protein (AGRP), 20 an agouti protein homologue, antagonizes MC4-R but not MC1-R. T. M. Fong *et al.*, *Biochem. Biophys. Res. Commun.* 237:629-631 (1997). Administration of AGRP in mice increases food intake and causes obesity but does not alter pigmentation. M. Rossi *et al.*, *Endocrinology*, 139:4428-4431 (1998). Together, this research indicates that MC4-R participates in energy 25 regulation, and therefore, identifies this receptor as a target for a rational drug design for the treatment of obesity.

In connection with MC4-R and its uncovered role in the etiology of obesity and food intake, the prior art includes reports of compounds and compositions that act as agonists or antagonists of MC4-R. As examples, U.S. Patent No. 6,060,589 describes polypeptides that are capable of 30 modulating signaling activity of melanocortin receptors. Also, U.S. Patent

Nos. 6,054,556 and 5,731,408 describe families of agonists and antagonists for MC4-R receptors that are lactam heptapeptides having a cyclic structure. WO 01/10842 discloses MC4-R binding compounds having a multitude of structures and methods of using such compounds to treat MC4-R associated disorders. Some of the compounds described include amidino- and guanidino-containing arenes and heteroarenes.

Various other classes of compounds have been disclosed as having MC4-R agonist activity. For example, WO 01/70708 and WO 00/74679 disclose MC4-R agonists that are piperidine compounds and derivatives, while WO 01/70337 and WO 99/64002 disclose MC-R agonists that are spiropiperidine derivatives. Other known melanocortin receptor agonists include aromatic amine compounds containing amino acid residues, particularly tryptophan residues, as disclosed in WO 01/55106. Similar agonists are disclosed in WO 01/055107 which comprise aromatic amine compounds containing tertiary amide or tertiary amine groups. Finally, WO 01/055109 discloses melanocortin receptor agonists comprising aromatic amines which are generally bisamides separated by a nitrogen-containing alkyl linker.

Guanidine-containing compounds having a variety of biological activities are also known in the prior art. For example, U.S. patent No. 4,732,916 issued to Satoh *et al.* discloses guanidine compounds useful as antiulcer agents; U.S. Patent No. 4,874,864, U.S. Patent No. 4,949,891, and U.S. Patent No. 4,948,901 issued to Schnur *et al.* and EP 0343 894 disclose guanidino compounds useful as protease inhibitors and as anti-plasmin and anti-thrombin agents; and U.S. Patent No. 5,352,704 issued to Okuyama *et al.* discloses a guanidino compound useful as an antiviral agent. Guanidine-containing compounds are also disclosed in other references. For example, U.S. Patent No. 6,030,985 issued to Gentile *et al.* discloses guanidine compounds useful for treating and preventing conditions in which inhibition of nitric oxide synthetase is beneficial such as stroke, schizophrenia, anxiety,

and pain. U.S. Patent No. 5,952,381 issued to Chen *et al.* discloses certain guanidine compounds for use in selectively inhibiting or antagonizing $\alpha_v\beta_3$ integrins.

Various 5-, 6-, and 7- membered fully saturated 1-
5 azacarbocyclic-2-ylidene derivatives of guanidine are disclosed as having anti-secretory and hypoglycemic activities by U.S. Patent No. 4,211,867 issued to Rasmussen. Such compounds are also taught as useful for the treatment of cardiovascular disease. Other guanidine derivatives are disclosed by U.S. Patent No. 5,885,985 issued to Macdonald *et al.* as useful
10 in therapy to treat inflammation.

Nevertheless, there remains a need for potent and specific agonists of MC4-R that are low molecular weight small molecules. Methods of treating a melanocortin-4 receptor mediated disease, such as obesity, with such small molecules and pharmaceutical formulations containing such small
15 molecules, are also particularly desirable.

SUMMARY OF THE INVENTION

The instant invention provides potent and specific agonists of MC4-R that are low molecular weight small molecules. Thus, there has been provided, in accordance with various aspects of the invention, compounds of formula IA, IIIA, IIIB, IVA, IVB, VA, VIA, VIIA, VIIB, VIIIA, VIIIB, and IXA as
20 described herein. Also provided are prodrugs of the compounds, pharmaceutically acceptable salts of the compounds, stereoisomers of the compounds, tautomers of the compounds, hydrates of the compounds, hydrides of the compounds, and solvates of the compounds.

One aspect of the invention provides a composition such as a
25 pharmaceutical formulation or medicament that includes at least one of the

compounds represented by the above-listed formulas and a pharmaceutically acceptable carrier.

Another aspect of the invention provides a method of treating an MC4-R mediated disease, comprising administering to a subject in need

5 thereof, at least one of the compounds represented by the above-listed formulas. The method may be used to treat diseases which include obesity or type II diabetes.

Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be

10 understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

15 The instant invention relates to novel classes of small molecule melanocortin-4 receptor (MC4-R) agonists. These compounds can be formulated into compositions and are useful in activating MC4-R, or in the treatment of MC4-R-mediated diseases, such as obesity, type II diabetes, erectile dysfunction, polycystic ovary disease, complications resulting from or

20 associated with obesity and diabetes, and Syndrome X.

The following definitions are used throughout this specification.

Alkyl groups include straight chain and branched alkyl groups having 1 to about 8 carbon atoms. Examples of straight chain alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl groups.

25 Examples of branched alkyl groups, include, but not limited to, isopropyl, sec-butyl, t-butyl, and isopentyl groups. Representative substituted alkyl groups

may be substituted one or more times with, for example, amino, thio, alkoxy, or halo groups such as F, Cl, Br, and I groups.

Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. Cycloalkyl groups also includes rings that are substituted with straight or branched chain alkyl groups as defined above, and further include cycloalkyl groups that are substituted with other rings including fused rings such as, but not limited to, decalinyl, tetrahydronaphthyl, and indanyl. Cycloalkyl groups also include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-, 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, alkyl, alkoxy, amino, thio, or halo groups.

Alkenyl groups are straight chain, branched or cyclic lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one double bond, as exemplified, for instance, by vinyl, propenyl, 2-butenyl, 3-butenyl, isobut enyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl groups among others.

Alkynyl groups are straight chain or branched lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one triple bond, as exemplified by groups, including, but not limited to, ethynyl, propynyl, and butynyl groups.

Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus aryl groups include, but are not limited to, phenyl, azulene, heptalene, biphenylene, indacene, fluorene, phenanthrene, triphenylene, pyrene, naphthacene, chrysene, biphenyl, anthracenyl, and naphthenyl groups. Although the phrase "aryl groups" includes groups

containing fused rings, such as fused aromatic-aliphatic ring systems, it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups. The phrase "aryl groups" includes groups

5 bonded to one or more carbon atom(s), and/or nitrogen atom(s), in the compounds of formulas I and II. Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or benzyl groups, which may be substituted with groups including, but not limited to, amino, alkoxy, alkyl, or

10 halo.

Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.

Arylalkyl groups are alkyl groups as defined above in which a

15 hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.

Heterocyclyl groups are nonaromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. The phrase "heterocyclyl group" includes fused

20 ring species including those comprising fused aromatic and nonaromatic groups. The phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to quinuclidyl. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, these are referred to as

25 "substituted heterocyclyl groups". Heterocyclyl groups include, but are not limited to, piperazino, morpholino, thiomorpholino, pyrrolidino, piperidino and homopiperazino groups. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to morpholino or piperazino groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or

disubstituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo.

Heteroaryl groups are aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Heteroaryl groups include, but are not limited to, groups such as furan, thiophene, pyrrole, isopyrrole, diazole, imidazole, isoimidazole, triazole, dithiole, oxathiole, isoxazole, oxazole, thiazole, isothiazole, oxadiazole, oxatriazole, dioxazole, oxathiazole, pyran, dioxin, pyridine, pyrimidine, pyridazine, pyrazine, triazine, oxazine, isoxazine, oxathiazine, azepin, oxepin, thiepin, diazepine, benzofuran, and isobenzofuran. Although the phrase "heteroaryl groups" includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heteroaryl groups". Representative substituted heteroaryl groups may be substituted one or more times with groups including, but not limited to, amino, alkoxy, alkyl, or halo.

Heterocyclalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocycl group as defined above.

Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above..

Aminocarbonyl groups are groups of the formula RR'NC(O)-, wherein R or R' may be the same or different, and each is independently selected from H, or substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycl or heteroaryl groups, as defined above.

In general, "substituted" refers to a group as defined above in which one or more bonds to a hydrogen atom contained therein are replaced

by a bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups and also substituted cycloalkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles.

Substituted cycloalkyl, substituted aryl, substituted heterocyclyl and substituted heteroaryl also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, substituted aryl, substituted heterocyclyl and substituted heteroaryl groups may be substituted with alkyl groups as defined above.


Pharmaceutically acceptable salts include a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid. As salts of inorganic bases, the invention includes, for example, alkali metals such as sodium or potassium, alkali earth metals such as calcium and magnesium or aluminum, and ammonia. As salts of organic bases, the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine. As salts of inorganic acids, the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid. As salts of organic acids, the instant invention includes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid,

-10-

citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. As salts of basic amino acids, the instant invention includes, for example, arginine, lysine and ornithine. Acidic amino acids include, for example, aspartic acid and glutamic acid.

5 Prodrugs, as used in the context of the instant invention, includes those derivatives of the instant compounds which undergo in vivo metabolic biotransformation, by enzymatic or nonenzymatic processes, such as hydrolysis, to form a compound of the invention. Prodrugs can be employed to improve pharmaceutical or biological properties, as for example
 10 solubility, melting point, stability and related physicochemical properties, absorption, pharmacodynamics and other delivery-related properties.

The instant invention provides potent and specific agonists of MC4-R that are low molecular weight small molecules. In accordance with one aspect of the invention, the invention provides a first group of compounds
 15 of formula IA as shown below.




Compounds of the invention further include prodrugs of the first group of compounds of formula IA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

20 In the first group of compounds of formula IA, V is selected from a carbon atom or is absent from the ring such that the carbon atom bonded to R¹⁶ is bonded to the carbon atom bonded to R¹⁹ forming a 5-membered ring.

-11-

In the first group of compounds of formula IA, Q, W, X, Y, and Z are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the compounds of formula IA, at least one of Q, W, X, Y, and Z is a nitrogen atom. In other embodiments of 5 the compounds of formula IA, Q, W, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IA, Q is a nitrogen atom and W, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IA, W is a nitrogen atom and Q, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IA, X is a nitrogen atom 10 and Q, W, Y, and Z are all carbon atoms. In still other embodiments of the compounds of formula IA, Y is a nitrogen atom and Q, W, X, and Z are all carbon atoms. In still other embodiments of the compounds of formula IA, Z is a nitrogen atom and Q, W, X, and Y are all carbon atoms.

In the first group of compounds of formula IA, R¹, R², R³, R⁴, and 15 R⁵ may be the same or different, and each may be independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, 20 arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB:



In the first group of compounds of formula IA, R¹ may be absent if W is a nitrogen atom, R² may be absent if X is a nitrogen atom, R³ may be absent if Z is a nitrogen atom, R⁴ may be absent if Y is a nitrogen atom, and

R^5 may be absent if Q is a nitrogen atom. In the first group of compounds of formula IA, at least one of R^1 , R^2 , R^3 , R^4 , or R^5 is a group having the formula IIA or IIB. In some embodiments of the compounds of formula IA, Q is a carbon atom and R^5 is a group of formula IIA or IIB.

5 In the first group of compounds of formula IA, R^1 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R^2 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, 10 aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In the first group of compounds of formula IA, R^1 and R^2 , together with the nitrogen to which they are bound, may form a substituted or unsubstituted heterocyclyl or heteroaryl group. In some embodiments of the compounds of formula IA, R^1 is H and R^2 is selected from the group 15 consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In other embodiments of the compounds of formula IA, R^1 is H and R^2 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and 20 thiophene groups. In still other embodiments of the compounds of formula IA, R^1 and R^2 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In various other embodiments of the compounds of formula IA, R^1 and R^2 may be the same or different and are each 25 independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In yet other embodiments of the compounds of formula IA, R^1 and R^2 , together with the nitrogen to which they 30 are bound, form a substituted or unsubstituted heterocyclyl group. In still other embodiments of the compounds of formula IA, R^1 and R^2 , together with

the nitrogen to which they are bound, form a substituted or unsubstituted saturated heterocycl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In another embodiment of the compounds of formula IA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still another embodiment of the compounds of formula IA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one oxygen heteroatom. In still other embodiments of the compounds of formula IA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group. In still further embodiments of the compounds of formula IA, R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the first group of compounds of formula IA, R³ is selected from the group consisting of H, and substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the first group of compounds of formula IA, R³ is selected from the group consisting of substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In one embodiment of the compounds of formula IA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl, alkenyl, alkyl, and aryl groups. In still other embodiments of the compounds of formula IA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-

alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-
5 alkoxyycyclohexyl, 3-alkoxyycyclohexyl, 4-alkoxyycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-
10 dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In still other embodiments of the
15 compounds of formula IA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-
20 trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the first group of compounds of formula IA, R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, 25 alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and heteroarylalkyl groups. In various embodiments of the compounds of formula IA, R⁴ is H.

In the first group of compounds of formula IA, R⁶ is selected 30 from the group consisting of H, substituted and unsubstituted alkyl groups,

substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the compounds of formula IA, R⁶ is H.

10 In the first group of compounds of formula IA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the compounds of formula IA, R⁷ is H.

15 In the first group of compounds of formula IA, R⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups including arylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl groups including heteroarylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In one embodiment of the compounds of formula IA, R⁸ is selected from the group consisting of substituted and unsubstituted arylalkyl groups, and substituted and unsubstituted heteroarylalkyl groups. In some embodiments of compounds of formula IA, R⁸ is a substituted or unsubstituted phenylalkyl group, a substituted or unsubstituted pyridylalkyl group, or a substituted or

unsubstituted indolylalkyl group. In other embodiments of the compounds of formula IA, R⁸ is a substituted or unsubstituted phenylalkyl group or a substituted or unsubstituted indolylalkyl group. In these embodiments of the compounds of formula IA, R⁸ may be a 2,4-disubstituted phenylmethyl group or an indolylmethyl group. In certain embodiments where R⁸ is a substituted arylalkyl or heteroarylalkyl, such as a phenylalkyl or pyridylalkyl, one substituent on the aryl or heteroaryl ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the characteristics described above. In some embodiments of the compounds of formula IA, R⁸ is selected from the group consisting of 2,4-dihalophenylmethyl, and 2,4-dialkylphenylmethyl groups. In still other embodiments of the compounds of formula IA, R⁸ is selected from the group consisting of phenylmethyl, 2,4-dichlorophenylmethyl, 4-methoxyphenylmethyl, 4-bromophenylmethyl, 4-methylphenylmethyl, 4-chlorophenylmethyl, 4-ethylphenylmethyl, cyclohexenylmethyl, 2-methoxyphenylmethyl, 2-chlorophenylmethyl, 2-fluorophenylmethyl, 3-methoxyphenylmethyl, 3-fluorophenylmethyl, thienylmethyl, indolylmethyl, 4-hydroxyphenylmethyl, 3,4-dimethoxyphenylmethyl, 2-chloro-4-iodophenylmethyl, 2-fluoro-4-methylphenylmethyl, 2-fluoro-4-bromophenylmethyl, 2-fluoro-4-methoxyphenylmethyl, 2-trifluoromethyl-4-fluorophenylmethyl, 2,4-difluorophenylmethyl, 2,4-dimethylphenylmethyl, and 2,4-dimethoxyphenylmethyl groups.

In the first group of compounds of formula IA, R⁹ is selected from the group consisting H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted 25 aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various 30 embodiments of the compounds of formula IA, R⁹ is H.

In the first group of compounds of formula IA, R¹⁰ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various 5 embodiments of the compounds of formula IA, R¹⁰ is H.

10

In the first group of compounds of formula IA, R¹¹, R¹², R¹³, R¹⁶, R¹⁷, and R¹⁸ are selected from the group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups, substituted and unsubstituted alkylcarbonylalkyl groups, 15 substituted and unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted -NH₂ groups, substituted and unsubstituted N(H)(alkyl) groups, substituted and 20 unsubstituted -NH(aryl) groups, substituted and unsubstituted -NH(heterocyclyl) groups, substituted and unsubstituted -N(alkyl)(aryl) groups, substituted and unsubstituted -N(alkyl)(heterocyclyl) groups, substituted and unsubstituted -N(aryl)(heterocyclyl) groups, substituted and unsubstituted -N(alkyl)₂ groups, substituted and unsubstituted -N(aryl)₂ groups, substituted 25 and unsubstituted -N(heterocyclyl)₂ groups, -C(=O)-OH groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted amide groups, substituted and unsubstituted sulfone groups, and substituted and unsubstituted sulfonamide groups. In the first group of compounds of 30 formula IA, R¹³ and R¹⁶ together can represent a double bond between the carbon atoms bonded to R¹³ and R¹⁶.


In the first group of compounds of formula IA, R^{14} and R^{15} are selected from the group consisting of H, and substituted and unsubstituted alkyl groups. In the first group of compounds of formula IA, R^{14} and R^{15} together with the two carbon atoms to which they are bound form a

5 substituted or unsubstituted, saturated or unsaturated, carbocyclic or heterocyclic ring comprising 5, 6, or 7 members. In one embodiment of the compounds of formula IA, R^{14} and R^{15} , together with the two carbon atoms to which they are bound, form a substituted or unsubstituted carbocyclic ring comprising 6 members.

10. In the first group of compounds of formula IA where V is absent, R^{17} and R^{18} are also absent.

In the first group of compounds of formula IA, R^{19} is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the compounds of formula IA, R^{19} is H.

In accordance with another aspect of the invention, the invention provides a second group of compounds of formula IIIA, as shown below




11A

Compounds of the invention further include prodrugs of the
20 second group of compounds of formula IIIA, pharmaceutically acceptable


salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

In the second group of compounds of formula IIIA, Q, W, X, Y, and Z are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the compounds of formula IIIA, at least one of Q, W, X, Y, and Z is a nitrogen atom. In other embodiments of the compounds of formula IIIA, Q, W, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IIIA, Q is a nitrogen atom and W, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IIIA, W is a nitrogen atom and Q, X, Y, and Z are all carbon atoms. In other embodiments of the compounds of formula IIIA, X is a nitrogen atom and Q, W, Y, and Z are all carbon atoms. In still other embodiments of the compounds of formula IIIA, Y is a nitrogen atom and Q, W, X, and Z are all carbon atoms. In still other embodiments of the compounds of formula IIIA, Z is a nitrogen atom and Q, W, X, and Y are all carbon atoms.

In the second group of compounds of formula IIIA, R¹, R², R³, R⁴, and R⁵ may be the same or different, and each may be independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.



IIA



IIB

-20-

In the second group of compounds of formula IIIA, R¹ may be absent if W is a nitrogen atom, R² may be absent if X is a nitrogen atom, R³ may be absent if Z is a nitrogen atom, R⁴ may be absent if Y is a nitrogen atom, and R⁵ may be absent if Q is a nitrogen atom. In the second group of 5 compounds of formula IIIA, one of R¹, R², R³, R⁴, or R⁵ is a group having the formula IIA or IIB. In some embodiments of the compounds of formula IIIA, Q is a carbon atom and R⁵ is a group of formula IIA or IIB.

In the second group of compounds of formula IIIA, R¹ is selected from the group consisting of H, and substituted and unsubstituted 10 alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R² is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In the second group of compounds having the formula 15 IIIA, R¹ and R², together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocycl or heteroaryl group. In some embodiments of the second group of compounds of formula IIIA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In other 20 embodiments of the second group of compounds of formula IIIA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the second group of 25 compounds of formula IIIA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In various other embodiments of the second group of compounds of formula IIIA, R¹ and R² may be the same or different and are each independently selected from the 30 group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-

fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the second group of compounds of formula IIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl group. In still other embodiments of the second 5 group of compounds of formula IIIA, R¹ and R², together with the nitrogen to which they are bound form a substituted or unsubstituted saturated heterocycl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In still other embodiments of the second group of 10 compounds of formula IIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the second group of compounds of formula IIIA, R¹ and R², together with the nitrogen to 15 which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one oxygen heteroatom. Representative examples of the above-described heterocycl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, 20 or azepino group. This includes compounds wherein R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the second group of compounds of formula IIIA, R³ is 25 selected from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In various embodiments of the second group of compounds of formula IIIA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic 30 cycloalkyl, alkenyl, alkyl, and aryl groups. In other embodiments of the second group of compounds of formula IIIA, R³ is selected from the group

consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl,

5 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamanyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In still other embodiments of the second group of compounds of formula IIIA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl,

20 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the second group of compounds of formula IIIA, R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, 30 and heteroarylalkyl groups. In various embodiments of the second group of compounds of formula IIIA, R⁴ is H.

In the second group of compounds of formula IIIA, R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the second group of compounds of formula IIIA, R⁶ is H.

In the second group of compounds of formula IIIA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the second group of compounds of formula IIIA, R⁷ is H.

In the second group of compounds of formula IIIA, R⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups including arylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl groups including heteroarylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In some embodiments of the second group of compounds of formula IIIA, R⁸ is selected from the group consisting of substituted and unsubstituted arylalkyl groups, and substituted and unsubstituted heteroarylalkyl groups. In some embodiments

of compounds of formula IIIA, R⁸ is a substituted or unsubstituted phenylalkyl group, a substituted or unsubstituted pyridylalkyl group, or a substituted or unsubstituted indolylalkyl group. In other embodiments of the second group of compounds of formula IIIA, R⁸ is a substituted or unsubstituted phenylalkyl group or a substituted or unsubstituted indolylalkyl group. More specifically, R⁸ may be a 2,4-disubstituted phenylmethyl group or an indolylmethyl group. In some embodiments of the second group of compounds of formula IIIA, R⁸ is selected from the group consisting of 2,4-dihalophenylmethyl, and 2,4-dialkylphenylmethyl groups. In certain embodiments where R⁸ is a substituted 5 arylalkyl or heteroarylalkyl, such as a phenylalkyl or pyridylalkyl, one substituent on the aryl or heteroaryl ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the characteristics described above. In 10 certain other embodiments of the second group of compounds of formula IIIA, R⁸ is selected from the group consisting of phenylmethyl, 2,4-dichlorophenylmethyl, 4-methoxyphenylmethyl, 4-bromophenylmethyl, 4-methylphenylmethyl, 4-chlorophenylmethyl, 4-ethylphenylmethyl, cyclohexenylmethyl, 2-methoxyphenylmethyl, 2-chlorophenylmethyl, 2-fluorophenylmethyl, 3-methoxyphenylmethyl, 3-fluorophenylmethyl, thienylmethyl, indolylmethyl, 4-hydroxyphenylmethyl, 3,4- 15 20 25

dimethoxyphenylmethyl, 2-chloro-4-iodophenylmethyl, 2-fluoro-4-methylphenylmethyl, 2-fluoro-4-bromophenylmethyl, 2-fluoro-4-methoxyphenylmethyl, 2-trifluoromethyl-4-fluorophenylmethyl, 2,4-difluorophenylmethyl, 2,4-dimethylphenylmethyl, or 2,4-dimethoxyphenylmethyl groups.

In the second group of compounds of formula IIIA, R⁹, R¹⁰, R¹¹, R¹², R¹⁵, R¹⁶, R¹⁷ and R¹⁸ are selected from the group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and unsubstituted alkoxy groups, and substituted and unsubstituted alkyl groups.

In the second group of compounds of formula IIIA, R¹³ and R¹⁴ 30 are selected from the group consisting of H, substituted and unsubstituted


alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted

5 -C(=O)-O(aryl) groups, -C(=O)-OH groups, -C(=O)-NH₂ groups, substituted and unsubstituted -C(=O)-N(H)(alkyl) groups, substituted and unsubstituted -C(=O)-N(alkyl)₂ groups, substituted and unsubstituted -C(=O)-N(H)(aryl) groups, substituted and unsubstituted -C(=O)-N(aryl)(alkyl) groups, substituted and unsubstituted -C(=O)-N(aryl)₂ groups, substituted and

10 unsubstituted -C(=O)-N(H)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(alkyl)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(heterocyclyl)₂ groups, and substituted and unsubstituted alkylsulfonylalkyl groups. In compounds of the second group having the

15 formula IIIA, R¹³ and R¹⁴ may alternatively join together with the carbon to which they are bound to form a substituted or unsubstituted carbocyclic or heterocyclic ring.

In some embodiments of the second group of compounds of formula IIIA, the compound of formula IIIA has the formula IIIB, as shown below.




wherein the dotted lines in the 6-membered carbocyclic ring indicate that the 6-membered ring is a substituted or unsubstituted cyclohexyl

or benzene ring. In this embodiment, A may be independently selected from the group consisting of a CH₂ group, a C(=O) group, a NH group, a substituted or unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group, a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl groups. In these embodiments, the variables in the formula IIIB have the same definition as defined above with respect to compounds of formula IIIA.

10 In various embodiments of compounds of formula IIIB wherein the 6-membered carbocyclic ring is a substituted benzene ring, one substituent on the benzene ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the characteristics described above.

15 In accordance with yet another aspect of the invention, the invention provides a third group of compounds of formula IVA, as shown below.



Compounds of the invention further include prodrugs of the third group of compounds of formula IVA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

In the third group of compounds of formula IVA, V is selected from a carbon atom or is absent from the ring such that the carbon atom

bonded to R^{28} is bonded to the carbon atom bonded to R^{15} forming a 5-membered ring.

In the third group of compounds of formula IVA, W, X, Y, and Z are independently selected from the group consisting of carbon atoms and 5 nitrogen atoms. In some embodiments of the third group of compounds of formula IVA, at least one of W, X, Y, and Z is a nitrogen atom whereas in other embodiments W, X, Y, and Z are all carbon atoms.

In the third group of compounds of formula IVA, R^1 , R^2 , R^3 , R^4 , 10 R^7 , R^8 , R^9 , and R^{10} are independently selected from the group consisting of H, Cl, F, Br, I, OH, -CN, -NO₂ substituted and unsubstituted alkoxy groups, and 15 substituted and unsubstituted alkyl groups.

In the third group of compounds of formula IVA, R^5 and R^6 are independently selected from the group consisting of H, substituted and 20 unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted -C(=O)-O(aryl) groups, -C(=O)-OH groups, -C(=O)-NH₂ groups, substituted and unsubstituted -C(=O)-N(H)(alkyl) groups, substituted and 25 unsubstituted -C(=O)-N(alkyl)₂ groups, substituted and unsubstituted -C(=O)-N(H)(aryl) groups, substituted and unsubstituted -C(=O)-N(aryl)(alkyl) groups, substituted and unsubstituted -C(=O)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(alkyl)(heterocyclyl) groups, substituted and unsubstituted 30 alkylsulfonylalkyl groups. In other compounds of the third group of compounds of formula IVA, R^5 and R^6 may alternatively join together with the carbon atom to which they are both bound to form a substituted or unsubstituted carbocyclic or heterocyclic ring.

In the third group of compounds of formula IVA, R¹¹ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the third group of 5 compounds of formula IVA, R¹¹ is H.

In the third group of compounds of formula IVA, R¹² is selected from the group consisting H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted 10 and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups including arylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl groups including heteroarylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted 15 heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In one embodiment of the third group of compounds of formula IVA, R¹² is selected from the group consisting of substituted and unsubstituted arylalkyl groups, and substituted and unsubstituted heteroarylalkyl groups. In some embodiments of 20 compounds of formula IVA, R¹² is a substituted or unsubstituted phenylalkyl group, a substituted or unsubstituted pyridylalkyl group, or a substituted or unsubstituted indolylalkyl group. In other embodiments of the third group of compounds of formula IVA, R¹² is a substituted or unsubstituted phenylalkyl group or a substituted or unsubstituted indolylalkyl group. Such embodiments 25 include those in which R¹² is a 2,4-disubstituted phenylmethyl group or an indolylmethyl group. These embodiments of the third group of compounds of formula IVA include those in which R¹² is selected from the group consisting of 2,4-dihalophenylmethyl, and 2,4-dialkylphenylmethyl groups. In certain embodiments where R¹² is a substituted arylalkyl or heteroarylalkyl, such as a 30 phenylalkyl or pyridylalkyl, one substituent on the aryl or heteroaryl ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the


characteristics described above. In still other embodiments of the third group of compounds of formula IVA, R¹² is selected from the group consisting of phenylmethyl, 2,4-dichlorophenylmethyl, 4-methoxyphenylmethyl, 4-bromophenylmethyl, 4-methylphenylmethyl, 4-chlorophenylmethyl, 4-ethylphenylmethyl, cyclohexenylmethyl, 2-methoxyphenylmethyl, 2-chlorophenylmethyl, 2-fluorophenylmethyl, 3-methoxyphenylmethyl, 3-fluorophenylmethyl, thienylmethyl, indolylmethyl, 4-hydroxyphenylmethyl, 3,4-dimethoxyphenylmethyl, 2-chloro-4-iodophenylmethyl, 2-fluoro-4-methylphenylmethyl, 2-fluoro-4-bromophenylmethyl, 2-fluoro-4-methoxyphenylmethyl, 2-trifluoromethyl-4-fluorophenylmethyl, 2,4-difluorophenylmethyl, 2,4-dimethylphenylmethyl, or 2,4-dimethoxyphenylmethyl groups.

In the third group of compounds of formula IVA, R¹³ and R¹⁴ are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the third group of compounds of formula IVA, R¹³ and/or R¹⁴ is(are) H.


In the third group of compounds of formula IVA, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In the third group of compounds of formula IVA where V is absent, R¹⁶ and R¹⁷ are also absent.

In the third group of compounds of formula IVA, R²⁰, R²², R²⁴, and, R²⁶ are independently selected from the group consisting of H,

substituted and unsubstituted alkyl groups, and groups having the formula IIA or IIB:



IIA



IIB

In the third group of compounds of formula IVA, R²⁰ may be absent if W is a nitrogen atom, R²² may be absent if X is a nitrogen atom, R²⁶ 5 may be absent if Z is a nitrogen atom, and R²⁴ may be absent if Y is a nitrogen atom. In the third group of compounds of formula IVA, at least one of R²⁰, R²², R²⁴ or R²⁶ is a group having the formula IIA or IIB. In some such embodiments, one of R²⁰, R²², R²⁴ or R²⁶ is a group having the formula IIA or IIB.

10 In the third group of compounds having the formula IVA, R^{1'} is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R^{2'} may be selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, 15 cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In the third group of compounds of formula IVA, R^{1'} and R^{2'}, together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocyclyl or heteroaryl group. In some embodiments of the third group of compounds of formula IVA, R^{1'} is H and R^{2'} 20 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In other embodiments of the third group of compounds of formula IVA, R^{1'} is H and R^{2'} is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-

methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the third group of compounds of formula IVA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In various other embodiments of the third group of compounds of formula IVA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the third group of compounds of formula IVA, R¹ and R², together with the nitrogen to which they are bound form a substituted or unsubstituted heterocyclyl group. In still other embodiments of the third group of compounds of formula IVA, R¹ and R², together with the nitrogen to which they are bound form a substituted or unsubstituted saturated heterocyclyl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the third group of compounds of formula IVA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the third group of compounds of formula IVA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one oxygen heteroatom. Representative examples of some of the above-described heterocyclyl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group. Other embodiments of the third group of compounds of formula IVA include those in which R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the third group of compounds having the formula IVA, R^{3'} is selected from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the third group of compounds of formula IVA, R^{3'} is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl, alkenyl, alkyl, and aryl groups. In other embodiments of the third group of compounds of formula IVA, R^{3'} is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In still other embodiments of the third group of compounds of formula IVA, R^{3'} is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl,

-33-


cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the third group of compounds having the formulas IVA, R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclylalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl groups, arylalkyl groups, and heteroarylalkyl groups. In various embodiments of the third group of compounds of formula IVA, R⁴ is H. In some embodiments of the third group of compounds, one, some or all of R⁴, R¹¹, R¹³, R¹⁴, and R¹⁵ is (are) all H.

10 In the third group of compounds of formula IVA, R²¹, R²³, R²⁵, and R²⁷ are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In the third group of compounds having the formula IVA, R²¹ and R²³ together can 15 alternatively represent a double bond between the carbons bonded to R²¹ and R²³. In compounds of the third group having the formula IVA, R²⁵ and R²⁷ together can alternatively represent a double bond between the carbons bonded to R²⁵ and R²⁷.

20 In the third group of compounds of formula IVA, R²⁸ and R²⁹ are independently selected from the group consisting of H, and substituted and unsubstituted alkyl groups. In the third group of compounds of formula IVA, R²⁸ and R²⁹ together can alternatively represent a double bond between the carbon atoms bonded to R²⁸ and R²⁹.


25 In one embodiment of the third group of compounds of formula IVA, the compound of formula IVA has the formula IVB below



wherein the dotted lines in the 6-membered carbocyclic ring indicate that the 6-membered ring is a substituted or unsubstituted cyclohexyl or benzene ring. In these embodiments, A may be independently selected from the group consisting of a CH_2 group, a $\text{C}(=\text{O})$ group, a NH group, a substituted or unsubstituted $\text{N}(\text{alkyl})$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{O}(\text{alkyl}))$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{NH}_2)$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{N}(\text{H})(\text{alkyl}))$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{N}(\text{H})(\text{aryl}))$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{N}(\text{alkyl})_2)$ group, a $\text{C}(\text{H})(\text{C}(=\text{O})-\text{N}(\text{aryl})_2)$ group, substituted and unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl groups. In these embodiments the variables in the formula IVB have the same definition as defined above with respect to compounds of formula IVA.

In various embodiments of compounds of formula IVB wherein the 6-membered carbocyclic ring is a substituted benzene ring, one substituent on the benzene ring is a group having the formula IIA or IIB, wherein R^1 , R^2 , R^3 , and R^4 have the characteristics described above.

In accordance with yet another aspect of the invention, the invention provides a fourth group of compounds of formula VA, as shown below.



VA


Compounds of the invention further include prodrugs of the fourth group of compounds of formula VA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

5 In the fourth group of compounds of formula VA, T is selected from the group consisting of O, S, and NR¹⁵ groups;

In the fourth group of compounds of formula VA, Q, W, X, Y, and Z are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the fourth group of compounds of formula VA, at least one of Q, W, X, Y, and Z is a nitrogen atom. In other embodiments of the fourth group of compounds of formula VA, Q, W, X, Y, and Z are all carbon atoms. In other embodiments of the fourth group of compounds of formula VA, Q is a nitrogen atom and W, X, Y, and Z are all carbon atoms. In other embodiments of the fourth group of compounds of formula VA, W is a nitrogen atom and Q, X, Y, and Z are all carbon atoms. In other embodiments of the fourth group of compounds of formula VA, X is a nitrogen atom and Q, W, Y, and Z are all carbon atoms. In still other embodiments of the fourth group of compounds of formula VA, Y is a nitrogen atom and Q, W, X, and Z are all carbon atoms. In still other embodiments of the fourth group of compounds of formula VA, Z is a nitrogen atom and Q, W, X, and Y are all carbon atoms.

In the fourth group of compounds of formula VA, R¹, R², R³, R⁴, and R⁵ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino,

5 dialkylamino, cycloalkyl, heterocycllamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB:



In the fourth group of compounds of formula VA, R¹ may be
 10 absent if W is a nitrogen atom, R² may be absent if X is a nitrogen atom, R³ may be absent if Z is a nitrogen atom, R⁴ may be absent if Y is a nitrogen atom, and R⁵ may be absent if Q is a nitrogen atom. In the fourth group of compounds of formula VA, at least one of R¹, R², R³, R⁴, or R⁵ is a group having the formula IIA or IIB. In one embodiment of the fourth group of
 15 compounds of formula VA, Q is a carbon atom and R⁵ is a group of formula IIA or IIB. In some embodiments of the fourth group of compounds of formula VA, one of R¹, R², R³, R⁴, or R⁵ is a group having the formula IIA or IIB.

In the fourth group of compounds of formula VA, R¹ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R² is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl

groups. In the fourth group of compounds of formula VA, R¹ and R², together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocycl or heteraryl group. In some embodiments of the fourth group of compounds of formula VA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In other embodiments of the fourth group of compounds of formula VA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the fourth group of compounds of formula VA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In various other embodiments of the fourth group of compounds of formula VA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In one embodiment of the fourth group of compounds of formula VA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl group. In still other embodiments of the fourth group of compounds of formula VA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted saturated heterocycl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the fourth group of compounds of formula VA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the fourth group of compounds of formula VA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted

heterocycl ring containing at least one oxygen heteroatom. Representative examples of some of the above-described heterocycl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, 5 piperidino, homopiperazino, or azepino group. Other embodiments of the fourth group of compounds of formula VA include those in which R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

10 In the fourth group of compounds of formula VA, R³ is selected from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the fourth group of compounds of formula VA, R³ is selected from the group 15 consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl, alkenyl, alkyl, and aryl groups. This embodiment contemplates that R³ may be selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, 30 cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-arylalkylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl,

4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In other embodiments of the fourth group of compounds of formula VA, R^{3'} is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-

5 dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-

10 isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the fourth group of compounds of formula VA, R^{4'} is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and

15 heteroarylalkyl groups. In various embodiments of the fourth group of compounds of formula VA, R^{4'} is H.

In the fourth group of compounds of formula VA, R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted

20 aryl groups, substituted and unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted

25 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments, of the fourth group of compounds of formula VA R⁶ is H.

In the fourth group of compounds of formula VA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups,

30 substituted and unsubstituted cycloalkyl groups, and substituted and

unsubstituted aryl groups. In various embodiments of the fourth group of compounds of formula VA, R⁷ is H.

In the fourth group of compounds of formula VA, R⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups including arylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl groups including heteroarylalkyl groups substituted with groups of formula IIA or IIB, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In one embodiment of the fourth group of compounds of formula VA, R⁸ is selected from the group consisting of substituted and unsubstituted arylalkyl groups, and substituted and unsubstituted heteroarylalkyl groups. In some embodiments of compounds of formula VA, R⁸ is a substituted or unsubstituted phenylalkyl group, a substituted or unsubstituted pyridylalkyl group, or a substituted or unsubstituted indolylalkyl group. In other embodiments of the fourth group of compounds of formula VA, R⁸ is a substituted or unsubstituted phenylalkyl group or a substituted or unsubstituted indolylalkyl group. In these embodiments of the fourth group of compounds of formula VA, R⁸ may be a 2,4-disubstituted phenylmethyl group or an indolylmethyl group. These embodiments contemplate that R⁸ may be selected from the group consisting of 2,4-dihalophenylmethyl, and 2,4-dialkylphenylmethyl groups. In certain embodiments where R⁸ is a substituted arylalkyl or heteroarylalkyl, such as a phenylalkyl or pyridylalkyl, one substituent on the aryl or heteroaryl ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the characteristics described above. In other embodiments of the fourth group of compounds of formula VA, R⁸ is selected from the group consisting of phenylmethyl, 2,4-dichlorophenylmethyl, 4-methoxyphenylmethyl, 4-

bromophenylmethyl, 4-methylphenylmethyl, 4-chlorophenylmethyl, 4-ethylphenylmethyl, cyclohexenylmethyl, 2-methoxyphenylmethyl, 2-chlorophenylmethyl, 2-fluorophenylmethyl, 3-methoxyphenylmethyl, 3-fluorophenylmethyl, thienylmethyl, indolylmethyl, 4-hydroxyphenylmethyl, 3,4-5 dimethoxyphenylmethyl, 2-chloro-4-iodophenylmethyl, 2-fluoro-4-methylphenylmethyl, 2-fluoro-4-bromophenylmethyl, 2-fluoro-4-methoxyphenylmethyl, 2-trifluoromethyl-4-fluorophenylmethyl, 2,4-difluorophenylmethyl, 2,4-dimethylphenylmethyl, or 2,4-dimethoxyphenylmethyl groups.

10 In the fourth group of compounds of formula VA, R⁹ is selected from the group consisting H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl 15 groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the fourth group of compounds of formula VA, R⁹ is H.

20 In the fourth group of compounds of formula VA, R¹⁰ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl 25 groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the fourth group of compounds of formula VA, R¹⁰ is H.

In the fourth group of compounds of formula VA, R^{11} , R^{12} , R^{13} , R^{14} , R^{16} , and R^{17} are selected from the group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and unsubstituted aryl groups, substituted and unsubstituted $-C(=O)$ -alkyl groups, substituted and unsubstituted

5 alkylcarbonylalkyl groups, substituted and unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -NH₂ groups, substituted and unsubstituted N(H)(alkyl) groups, substituted and unsubstituted -NH(aryl) groups, substituted and unsubstituted -NH(heterocycl) groups, substituted and unsubstituted -N(alkyl)(aryl) groups, substituted and unsubstituted -N(alkyl)(heterocycl) groups, substituted and unsubstituted -N(aryl)(heterocycl) groups,

10 substituted and unsubstituted -N(alkyl)₂ groups, substituted and unsubstituted -N(aryl)₂ groups, substituted and unsubstituted -N(heterocycl)₂ groups, -C(=O)-OH groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted amide groups, substituted and unsubstituted sulfone groups, and substituted and unsubstituted sulfonamide groups.

15 20 In the fourth group of compounds of formula VA, R^{15} is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups.

25


In one embodiment, T is an NR¹⁵ group and R¹⁴ and R¹⁵ together with the atoms to which they are bound form a substituted or unsubstituted heterocyclic ring comprising 6 members.

In the fourth group of compounds of formula VA, R^{12} and R^{14}

5 together with the carbon atoms to which they are bound, may form a substituted or unsubstituted, saturated or unsaturated carbocyclic or heterocyclic ring comprising 5 or 6 members. In the fourth group of compounds of formula VA, R¹⁴ and R¹⁵ together with the atoms to which they are bound, may form a substituted or unsubstituted, saturated or unsaturated 10 heterocyclic ring comprising 5 or 6 members.

In the fourth group of compounds of formula VA, R¹⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the fourth group of compounds of formula VA, R¹⁸ is H.

In accordance with another aspect of the invention, the invention provides a fifth group of compounds of formula VIA as shown below.



Compounds of the invention further include prodrugs of the fifth group of compounds of formula VIA, pharmaceutically acceptable salts

thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

In the fifth group of compounds of formula VIA, V is selected from a carbon atom or is absent from the ring such that the carbon atom 5 bonded to R¹⁵ is bonded to the carbon atom bonded to R¹⁸ forming a 5-membered ring.

In the fifth group of compounds of formula VIA, Q', W', X', Y', and Z' are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the fifth group of compounds of 10 formula VIA, at least one of Q', W', X', Y', and Z' is a nitrogen atom. In other embodiments of the fifth group of compounds of formula VIA, Q', W', X', Y', and Z' are all carbon atoms. In other embodiments of the fifth group of compounds of formula VIA, Q' is a nitrogen atom and W', X', Y', and Z' are all carbon atoms. In other embodiments of the fifth group of compounds of 15 formula VIA, W' is a nitrogen atom and Q', X', Y', and Z' are all carbon atoms. In other embodiments of the fifth group of compounds of formula VIA, X' is a nitrogen atom and Q', W', Y', and Z' are all carbon atoms. In still other embodiments of the fifth group of compounds of formula VIA, Y' is a nitrogen atom and Q', W', X', and Z' are all carbon atoms. In still other embodiments 20 of the fifth group of compounds of formula VIA, Z' is a nitrogen atom and Q', W', X', and Y' are all carbon atoms.

In the fifth group of compounds of formula VIA, R¹, R², R³, R⁴, and R⁵ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted 25 and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.

In the fifth group of compounds of formula VIA, R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the fifth group of compounds of formula VIA, R⁶ is H.

In the fifth group of compounds of formula VIA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the fifth group of compounds of formula VIA, R⁷ is H.

In the fifth group of compounds of formula VIA, R⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups.

In the fifth group of compounds of formula VIA, R⁹ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl

groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various 5 embodiments of the fifth group of compounds of formula VIA, R⁹ is H.

In the fifth group of compounds of formula VIA, R¹⁰, R¹¹, R¹², R¹⁵, R¹⁶, and R¹⁷ are selected from the group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups, substituted and unsubstituted alkylcarbonylalkyl groups, 10 substituted and unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -NH₂ groups, substituted and unsubstituted N(H)(alkyl) groups, substituted and 15 unsubstituted -NH(aryl) groups, substituted and unsubstituted -NH(heterocycl) groups, substituted and unsubstituted -N(alkyl)(aryl) groups, substituted and unsubstituted -N(alkyl)(heterocycl) groups, substituted and unsubstituted -N(aryl)(heterocycl) groups, substituted and unsubstituted -N(alkyl)₂ groups, substituted and unsubstituted -N(aryl)₂ groups, substituted 20 and unsubstituted -N(heterocycl)₂ groups, -C(=O)-OH groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted amide groups, substituted and unsubstituted sulfone groups, and substituted and unsubstituted sulfonamide groups. In the fifth group of compounds of 25 formula VIA, R¹² and R¹⁵ together may alternatively represent a double bond between the carbon atoms bonded to R¹² and R¹⁵.


In the fifth group of compounds of formula VIA, R¹³ and R¹⁴ are selected from the group consisting of H, and substituted and unsubstituted alkyl groups. Alternatively, R¹³ and R¹⁴ together with the two carbon atoms to 30 which they are bound form a substituted or unsubstituted, saturated or

unsaturated, carbocyclic or heterocyclic ring comprising 5, 6, or 7 members. In one embodiment of the fifth group of compounds of formula VIA, R¹³ and R¹⁴, together with the two carbon atoms to which they are bound, form a substituted or unsubstituted carbocyclic ring comprising 6 members.

5 In the fifth group of compounds of formula VIA, R¹⁸ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the fifth group of compounds of formula VIA, R¹⁸ is H.

10 In compounds of formula VIA where V is absent, R¹⁶ and R¹⁷ are also absent.

In the fifth group of compounds of formula VIA, R¹⁹, R²⁰, R²¹, R²², and R²³ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and 15 substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, heteroarylaminocarbonyl groups and groups of formula IIA or IIB.



IIA

IIB

20 In the fifth group of compounds of formula VIA, R²² may be absent if W' is a nitrogen atom, R²³ may be absent if X' is a nitrogen atom, R¹⁹ may be absent if Z' is a nitrogen atom, R²⁰ may be absent if Y' is a nitrogen atom, and R²¹ may be absent if Q' is a nitrogen atom. In the fifth group of

compounds of formula VIA, at least one of R^{19} , R^{20} , R^{21} , R^{22} , or R^{23} is a group having the formula IIA or IIB. In some embodiments of the fifth group of compounds of formula VIA, Q' is a carbon atom and R^{21} is a group of formula IIA or IIB. In some embodiments of the fifth group of compounds of formula

5 VIA, one of R^{19} , R^{20} , R^{21} , R^{22} , or R^{23} is a group having the formula IIA or IIB

In the fifth group of compounds having the formula VIA, R^1 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R^2 is selected from the group

10 consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In the fifth group of compounds having the formula VIA, R^1 and R^2 , together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocyclyl or heteroaryl group. In some

15 embodiments of the fifth group of compounds of formula VIA, R^1 is H and R^2 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In other embodiments of the fifth group of compounds of formula VIA, R^1 is H and R^2 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl,

20 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the fifth group of compounds of formula VIA, R^1 and R^2 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl

25 groups. In various other embodiments of the fifth group of compounds of formula VIA, R^1 and R^2 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-

30 chlorobenzyl, and thiophene groups. In still other embodiments of the fifth group of compounds of formula VIA, R^1 and R^2 , together with the nitrogen to

which they are bound, form a substituted or unsubstituted heterocyclyl group. In some embodiments of the fifth group of compounds of formula VIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted saturated heterocyclyl group comprising at least one

5 heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the fifth group of compounds of formula VIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one nitrogen heteroatom in addition to the

10 nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the fifth group of compounds of formula VIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one oxygen heteroatom. Representative examples of some of the above-described heterocyclyl embodiments include

15 those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group. Other embodiments of the fifth group of compounds of formula VIA include those in which R¹ and R², together with the nitrogen to which they are bound, form a substituted

20 piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the fifth group of compounds having the formula VIA, R³ is selected from the group consisting of H, and substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the fifth group of compounds having the formula VIA, R³ is selected from the group consisting of substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the fifth group of compounds of formula VIA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl,


-50-

alkenyl, alkyl, and aryl groups. In other embodiments of the fifth group of compounds of formula VIA, R^{3'} is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-arylcylohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In still other embodiments of the fifth group of compounds of formula VIA, R^{3'} is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the fifth group of compounds of formula VIA, R^{4'} is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and

heteroarylalkyl groups. In various embodiments of the fifth group of compounds of formula VIA, $R^{4'}$ is H.

In accordance with another aspect of the invention, the invention provides a sixth group of compounds of formula VIIA, as shown below.



5 Compounds of the invention further include prodrugs of the sixth group of compounds of formula VIIA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

In the sixth group of compounds of formula VIIA, Q', W', X', Y',

10 and Z' are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the sixth group of compounds of formula VIIA, at least one of Q', W', X', Y', and Z' is a nitrogen atom. In other embodiments of the sixth group of compounds of formula VIIA, Q', W', X', Y', and Z' are all carbon atoms. In other embodiments of the sixth group of compounds of formula VIIA, Q' is a nitrogen atom and W', X', Y', and Z' are all carbon atoms. In other embodiments of the sixth group of compounds of formula VIIA, W' is a nitrogen atom and Q', X', Y', and Z' are all carbon atoms. In other embodiments of the sixth group of compounds of formula VIIA, X' is a nitrogen atom and Q', W', Y', and Z' are all carbon atoms. In still other embodiments of the sixth group of compounds of formula VIIA, Y' is a nitrogen

15

20

atom and Q', W', X', and Z' are all carbon atoms. In still other embodiments of the sixth group of compounds of formula VIIA, Z' is a nitrogen atom and Q'; W', X', and Y' are all carbon atoms.

In the sixth group of compounds of formula VIIA, R¹, R², R³, R⁴, 5 and R⁵ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino; heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, 10 arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.

In the sixth group of compounds of formula VIIA, R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted 15 aryl groups, substituted and unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted 20 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the sixth group of compounds of formula VIIA, R⁶ is H.


In the sixth group of compounds of formula VIIA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and 25 unsubstituted aryl groups. In various embodiments of the sixth group of compounds of formula VIIA, R⁷ is H.

In the sixth group of compounds of formula VIIA, R⁸, R⁹, R¹⁰, R¹¹, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are selected from the group consisting of H, Cl, F,

Br, I, -CN, -OH, -NO₂, substituted and unsubstituted alkoxy groups, and substituted and unsubstituted alkyl groups.

In the sixth group of compounds of formula VIIA, R¹² and R¹³ are selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted -C(=O)-O(aryl) groups, -C(=O)-OH groups, -C(=O)-NH₂ groups, substituted and unsubstituted -C(=O)-N(H)(alkyl) groups, substituted and unsubstituted -C(=O)-N(alkyl)₂ groups, substituted and unsubstituted -C(=O)-N(H)(aryl) groups, substituted and unsubstituted -C(=O)-N(aryl)(alkyl) groups, substituted and unsubstituted -C(=O)-N(aryl)₂ groups, substituted and unsubstituted -C(=O)-N(H)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(alkyl)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted -C(=O)-N(heterocyclyl)₂ groups, and substituted and unsubstituted alkylsulfonylalkyl groups. In the sixth group of compounds of formula VIIA, R¹² and R¹³ may alternatively join together with the carbon to which they are bound to form a substituted or unsubstituted carbocyclic or heterocyclic ring including carbocyclic or heterocyclic rings substituted with a group of formula IIA or IIB.

In the sixth group of compounds of formula VIIA, R¹⁸, R¹⁹, R²⁰, R²¹, and R²² may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.



In the sixth group of compounds of formula VIIA, R^{21} may be absent if W' is a nitrogen atom, R^{22} may be absent if X' is a nitrogen atom, R^{18} may be absent if Z' is a nitrogen atom, R^{19} may be absent if Y' is a nitrogen atom, and R^{20} may be absent if Q' is a nitrogen atom. In the sixth group of 5 compounds of formula VIIA, at least one of R^{18} , R^{19} , R^{20} , R^{21} , or R^{22} is a group having the formula IIA or IIB. In one embodiment of the sixth group of compounds of formula VIIA, Q' is a carbon atom and R^{20} is a group of formula IIA or IIB. In some embodiments of the sixth group of compounds of formula VIIA, one of R^{18} , R^{19} , R^{20} , R^{21} , or R^{22} is a group having the formula IIA or IIB

10 In the sixth group of compounds of formula VIIA, R^1 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R^2 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, 15 aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In the sixth group of compounds having the formula VIIA, R^1 and R^2 , together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocyclyl or heteroaryl group. In one embodiment of the sixth group of compounds of formula VIIA, R^1 is H and R^2 is selected from the group consisting of substituted and unsubstituted alkyl, 20 arylalkyl, and heteroarylalkyl groups. In other embodiments of the sixth group of compounds of formula VIIA, R^1 is H and R^2 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-

methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the sixth group of compounds of formula VIIA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and

5 heteroarylalkyl groups. In various embodiments of the sixth group of compounds of formula VIIA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-

10 chlorobenzyl, and thiophene groups. In other embodiments of the sixth group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound form a substituted or unsubstituted heterocycl group. In still other embodiments of the sixth group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or

15 unsubstituted saturated heterocycl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the sixth group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted

20 heterocycl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the sixth group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one oxygen heteroatom. Representative

25 examples of some of the above-described heterocycl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group. In other embodiments of the sixth group of compounds of formula VIIA, R¹ and R², together with the


30 nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the sixth group of compounds having the formula VIIA, R³ is selected from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In some embodiments of the sixth group of compounds of formula VIIA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl, alkenyl, alkyl, and aryl groups. In other embodiments of the sixth group of compounds of formula VIIA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-arylcylohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In still other embodiments of the sixth group of compounds of formula VIIA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl,

cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the sixth group of compounds having the formula VIIA, R^{4'} is selected from the group consisting of H, and substituted and unsubstituted 5 alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and heteroarylalkyl groups. In various embodiments of the sixth group of compounds of formula VIIA, R^{4'} is H.

In one embodiment of the sixth group of compounds of formula 10 VIIA, the compound of formula VIIA has the formula VIIB, as shown below.




wherein the dotted lines in the 6-membered carbocyclic ring indicate that the 6-membered ring is a substituted or unsubstituted cyclohexyl or benzene ring. In this embodiment, A may be independently selected from the group consisting of a CH₂ group, a C(=O) group, a NH group, a 15 substituted or unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group, a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl groups. In these embodiments the variables in the

formula VIIB have the same definition as defined above with respect to compounds of formula IVA.

In various embodiments of compounds of formula VIIB wherein the 6-membered carbocyclic ring is a substituted benzene ring, one 5 substituent on the benzene ring is a group having the formula IIA or IIB, wherein R¹, R², R³, and R⁴ have the characteristics described above.

In accordance with yet another aspect of the invention, the invention provides a seventh group of compounds of formula VIIIA, as shown below.



10 Compounds of the invention further include prodrugs of the seventh group of compounds having the formula VIIIA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

15 In the seventh group of compounds of formula VIIIA, V is selected from a carbon atom or is absent from the ring such that the carbon atom bonded to R²⁷ is bonded to the carbon atom bonded to R¹⁴ forming a 5-membered ring.

In the seventh group of compounds of formula VIIIA, W, X, Y, and Z are independently selected from the group consisting of carbon atoms and nitrogen atoms.

In the seventh group of compounds of formula VIIIA, Q', W', X',

- 5 Y', and Z' are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the seventh group of compounds of formula VIIIA, at least one of Q', W', X', Y', and Z' is a nitrogen atom. In other embodiments of the seventh group of compounds of formula VIIIA, Q', W', X', Y', and Z' are all carbon atoms. In other embodiments of the seventh group of compounds of formula VIIIA, Q' is a nitrogen atom and W', X', Y', and Z' are all carbon atoms. In other embodiments of the seventh group of compounds of formula VIIIA, W' is a nitrogen atom and Q', X', Y', and Z' are all carbon atoms. In other embodiments of the seventh group of compounds of formula VIIIA, X' is a nitrogen atom and Q', W', Y', and Z' are all carbon atoms. In still other embodiments of the seventh group of compounds of formula VIIIA, Y' is a nitrogen atom and Q', W', X', and Z' are all carbon atoms. In still other embodiments of the seventh group of compounds of formula VIIIA, Z' is a nitrogen atom and Q', W', X', and Y' are all carbon atoms.
- 10
- 15

- 20 In the seventh group of compounds of formula VIIIA, R¹, R², R³, R⁴, R⁷, R⁸, R⁹, and R¹⁰ are independently selected from the group consisting of H, Cl, F, Br, I, OH, -CN, -NO₂ substituted and unsubstituted alkoxy groups, and substituted and unsubstituted alkyl groups.

In the seventh group of compounds of formula VIIIA, R⁵ and R⁶

- 25 are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted -C(=O)-O(alkyl) groups, substituted and unsubstituted -C(=O)-O(aryl) groups, -C(=O)-OH groups, -C(=O)-NH₂ groups,
- 30

substituted and unsubstituted $-C(=O)-N(H)(alkyl)$ groups, substituted and unsubstituted $-C(=O)-N(alkyl)_2$ groups, substituted and unsubstituted $-C(=O)-N(H)(aryl)$ groups, substituted and unsubstituted $-C(=O)-N(aryl)(alkyl)$ groups, substituted and unsubstituted $-C(=O)-N(aryl)_2$ groups, substituted and 5 unsubstituted $-C(=O)-N(H)(heterocyclyl)$ groups, substituted and unsubstituted $-C(=O)-N(alkyl)(heterocyclyl)$ groups, substituted and unsubstituted $-C(=O)-N(aryl)(heterocyclyl)$ groups, substituted and unsubstituted $-C(=O)-N(heterocyclyl)_2$ groups, and substituted and unsubstituted alkylsulfonylalkyl groups. In the seventh group of compounds of formula 10 VIII A, R^5 and R^6 may alternatively join together with the carbon to which they are bound form a substituted or unsubstituted carbocyclic or heterocyclic ring including carbocyclic or heterocyclic rings substituted with a group of formula IIA or IIB.

In the seventh group of compounds of formula VIII A, R^{11} is 15 selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the seventh group of compounds of formula VIII A, R^{11} is H.


In the seventh group of compounds of formula VIII A, R^{12} and R^{13} 20 are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted 25 arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the seventh group of compounds of formula VIII A, R^{12} and/or R^{13} is(are) H.

In the seventh group of compounds of formula VIIIA, R¹⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ are independently selected from H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In the seventh group of 5 compounds of formula VIIIA where V is absent, R¹⁵ and R¹⁶ are also absent.

In the seventh group of compounds of formula VIIIA, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, and, R²⁶ are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl 10 groups. In the seventh group of compounds of formula VIIIA, R¹⁹ may be absent if W is a nitrogen atom, R²¹ may be absent if X is a nitrogen atom, R²⁵ may be absent if Z is a nitrogen atom, and R²³ may be absent if Y is a nitrogen atom. In the seventh group of compounds of formula VIIIA, R²⁰ and R²² together can alternatively represent a double bond between the carbons 15 bonded to R²⁰ and R²². In the seventh group of compounds of formula VIIIA, R²⁴ and R²⁶ together can alternatively represent a double bond between the carbons bonded to R²⁴ and R²⁶.

In the seventh group of compounds of formula VIIIA, R²⁷ and R²⁸ are independently selected from the group consisting of H and substituted and 20 unsubstituted alkyl groups. In the seventh group of compounds of formula VIIIA, R²⁷ and R²⁸ together may alternatively represent a double bond between the carbon atoms bonded to R²⁷ and R²⁸.

In the seventh group of compounds of formula VIIIA, R²⁹, R³⁰, R³¹, R³² and, R³³ may be the same or different and are independently 25 selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, 30 heteroarylaminocarbonyl groups, and groups having the formula IIA or IIB.



In the seventh group of compounds of formula VIIIA, R³¹ may be absent if Q' is a nitrogen atom, R³² may be absent if W' is a nitrogen atom, R³³ may be absent if X' is a nitrogen atom, R²⁹ may be absent if Z' is a nitrogen atom, and R³⁰ may be absent if Y' is a nitrogen atom. In the seventh group of 5 compounds of formula VIIIA, at least one of R²⁹, R³⁰, R³¹, R³², or R³³ is a group having the formula IIA or IIB. In some embodiments of the seventh group of compounds of formula VIIIA, one of R²⁹, R³⁰, R³¹, R³², or R³³ is a group having the formula IIA or IIB.

In the seventh group of compounds having the formula VIIIA, R¹ 10 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, and R² is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl 15 groups. In the seventh group of compounds of formula VIIIA, R¹ and R², together with the nitrogen to which they are bound, may alternatively form a substituted or unsubstituted heterocyclyl or heteroaryl group. In one embodiment of the seventh group of compounds of formula VIIIA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted 20 alkyl, arylalkyl, and heteroarylalkyl groups. In other embodiments of the seventh group of compounds of formula VIIIA, R¹ is H and R² is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still

other embodiments of the seventh group of compounds of formula VIIA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. In various other embodiments of the seventh group of compounds of formula VIIA, R¹ and R² may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other embodiments of the seventh group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl group. In still further embodiments of the seventh group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted saturated heterocyclyl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the seventh group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments of the seventh group of compounds of formula VIIA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl ring containing at least one oxygen heteroatom. Representative examples of some of the above-described heterocyclyl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group. Still other embodiments of the seventh group of compounds having the formula VIIA include those in which R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.


In the seventh group of compounds having the formula VIIIA, R³ is selected from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In various embodiments 5 of the seventh group of compounds of formula VIIIA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl, alkenyl, alkyl, and aryl groups. In other embodiments of the seventh group of compounds of formula VIIIA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- 10 dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- 15 diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxyycyclohexyl, 2,4-dialkoxyycyclohexyl, 3,4-dialkoxyycyclohexyl, 2,5-dialkoxyycyclohexyl, 2,6-dialkoxyycyclohexyl, 2,2-dialkoxyycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- 20 dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, 25 bornyl, norbornyl, and decalinyl groups. In still other embodiments of the seventh group of compounds of formula VIIIA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, 30

cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the seventh group of compounds having the formulas VIIIA, R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and heteroarylalkyl groups. In various embodiments of the seventh group of compounds of formula VIIIA, R⁴ is H.

5

In one embodiment of the seventh group of compounds of formula VIIIA, the compound of formula VIIIA has the formula VIIIB below



wherein the dotted lines in the 6-membered carbocyclic ring indicate that the 6-membered ring is a substituted or unsubstituted cyclohexyl or benzene ring. In these embodiments, A may be independently selected from the group consisting of a CH₂ group, a C(=O) group, a NH group, a substituted or unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group, a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl groups. In these embodiments the variables in the

10


15

formula VIIIB have the same definition as defined above with respect for compounds of formula VIIIA.

In various embodiments of compounds of formula VIIIB wherein the 6-membered carbocyclic ring is a substituted benzene ring, one

5 substituent on the benzene ring is a group having the formula IIA or IIB, wherein R^1 , R^2 , R^3 , and R^4 have the characteristics described above

In accordance with yet another aspect of the invention, the invention provides an eighth group of compounds of formula IXA, as shown below.



10 Compounds of the invention further include prodrugs of the eighth group of compounds of formula IXA, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, and solvates thereof.

In the eighth group of compounds of formula I_{XA}, T may be selected from the group consisting of O, S, and NR¹⁴ groups.

In the eighth group of compounds of formula IXA, Q', W', X', Y', and Z' are independently selected from the group consisting of carbon atoms and nitrogen atoms. In some embodiments of the eighth group of compounds of formula IXA, at least one of Q', W', X', Y', and Z' is a nitrogen atom. In

other embodiments of the eighth group of compounds of formula IXA, Q', W', X', Y', and Z' are all carbon atoms. In other embodiments of the eighth group of compounds of formula IXA, Q' is a nitrogen atom and W', X', Y', and Z' are all carbon atoms. In other embodiments of the eighth group of compounds of formula IXA, W' is a nitrogen atom and Q', X', Y', and Z' are all carbon atoms. In other embodiments of the eighth group of compounds of formula IXA, X' is a nitrogen atom and Q', W', Y', and Z' are all carbon atoms. In still other embodiments of the eighth group of compounds of formula IXA, Y' is a nitrogen atom and Q', W', X', and Z' are all carbon atoms. In still other embodiments of the eighth group of compounds of formula IXA, Z' is a nitrogen atom and Q', W', X', and Y' are all carbon atoms.

In the eighth group of compounds of formula IXA, R¹, R², R³, R⁴, and R⁵ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.

In the eighth group of compounds of formula IXA, R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various embodiments of the eighth group of compounds of formula IXA, R⁶ is H.

In the eighth group of compounds of formula IXA, R⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the eighth group of

5 compounds of formula IXA, R⁷ is H.

In the eighth group of compounds of formula IXA, R⁸ is selected from the group consisting H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various

10 15 embodiments of the eighth group of compounds of formula IXA, R⁸ is H.

In the eighth group of compounds of formula IXA, R⁹ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups. In various

20 25 embodiments of the eighth group of compounds of formula IXA, R⁹ is H.

In the eighth group of compounds of formula IXA, R¹⁰, R¹¹, R¹², R¹³, R¹⁵, and R¹⁶ are selected from the group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups, substituted and unsubstituted alkylcarbonylalkyl groups,

30 substituted and unsubstituted alkoxy groups, substituted and unsubstituted

aryloxy groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted $-NH_2$ groups, substituted and unsubstituted $N(H)(alkyl)$ groups, substituted and unsubstituted $-NH(aryl)$ groups, substituted and unsubstituted $-NH(heterocyclyl)$ groups, substituted and unsubstituted $-N(alkyl)(aryl)$ groups, substituted and unsubstituted $-N(alkyl)(heterocyclyl)$ groups, substituted and unsubstituted $-N(aryl)(heterocyclyl)$ groups, substituted and unsubstituted $-N(alkyl)_2$ groups, substituted and unsubstituted $-N(aryl)_2$ groups, substituted and unsubstituted $-N(heterocyclyl)_2$ groups, $-C(=O)-OH$ groups, substituted and unsubstituted $-C(=O)-O(alkyl)$ groups, substituted and unsubstituted amide groups, substituted and unsubstituted sulfone groups, and substituted and unsubstituted sulfonamide groups.

15 In the eighth group of compounds of formula IXA, R^{14} is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups, substituted and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups.

20 In one embodiment of the eighth group of compounds of formula IXA, T is an NR^{14} group and R^{13} and R^{14} together with the two atoms to which they are bound form a substituted or unsubstituted heterocyclic ring comprising 6 members.


25 In the eighth group of compounds of formula IXA, R^{11} and R^{13} together with the carbon atoms to which they are bound, may alternatively form a substituted or unsubstituted, saturated or unsaturated carbocyclic or

heterocyclic ring comprising 5 or 6 members. In the eighth group of compounds of formula IXA, R¹³ and R¹⁴ together with the atoms to which they are bound, may alternatively form a substituted or unsubstituted, saturated or unsaturated heterocyclic ring comprising 5 or 6 members;


5 In the eighth group of compounds of formula IXA, R¹⁷ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl groups. In various embodiments of the eighth group of compounds of formula IXA, R¹⁷ is H.

10 In the eighth group of compounds of formula IXA, R¹⁸, R¹⁹, R²⁰, R²¹, and R²² may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, heteroarylaminocarbonyl groups, and groups of formula IIA or IIB.

15 16



IIA



IIB

17 In the eighth group of compounds of formula IXA, R²¹ may be absent if W' is a nitrogen atom, R²² may be absent if X' is a nitrogen atom, R¹⁸ may be absent if Z' is a nitrogen atom, R¹⁹ may be absent if Y' is a nitrogen atom, and R²⁰ may be absent if Q' is a nitrogen atom. In the eighth group of compounds of formula IXA, at least one of R¹⁸, R¹⁹, R²⁰, R²¹, or R²² is a group having the formula IIA or IIB. In one embodiment of the eighth group of

compounds of formula IXA, Q' is a carbon atom and R²⁰ is a group of formula IIA or IIB. In some embodiments of the eighth group of compounds of formula IXA, at one of R¹⁸, R¹⁹, R²⁰, R²¹, or R²² is a group having the formula IIA or IIB

In the eighth group of compounds of formula IXA, R¹ is selected
5 from the group consisting of H, and substituted and unsubstituted alkyl,
alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl,
heteroarylalkyl, and cycloalkylalkyl groups, and R² is selected from the group
consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl,
aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
10 groups. In the eighth group of compounds of formula IXA, R¹ and R²,
together with the nitrogen to which they are bound, form a substituted or
unsubstituted heterocyclyl or heteroaryl group. In some embodiments of the
eighth group of compounds of formula IXA, R¹ is H and R² is selected from
the group consisting of substituted and unsubstituted alkyl, arylalkyl, and
15 heteroarylalkyl groups. In other embodiments of the eighth group of
compounds of formula IXA, R¹ is H and R² is selected from the group
consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl,
3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-
methoxybenzyl, 2-chlorobenzyl, and thiophene groups. In still other
20 embodiments of the eighth group of compounds of formula IXA, R¹ and R²
may be the same or different and are each independently selected from the
group consisting of substituted and unsubstituted alkyl, arylalkyl, and
heteroarylalkyl groups. In various embodiments of the eighth group of
compounds of formula IXA, R¹ and R² may be the same or different and are
25 each independently selected from the group consisting of substituted and
unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-
dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-
chlorobenzyl, and thiophene groups. In one embodiment of the eighth group
30 of compounds of formula IXA, R¹ and R², together with the nitrogen to which
they are bound, form a substituted or unsubstituted heterocyclyl group. In
other embodiments of the eighth group of compounds of formula VIIIA, R¹

and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted saturated heterocycl group comprising at least one heteroatom selected from the group consisting of O, S, and N, in addition to the nitrogen atom to which R¹ and R² are bound. In other embodiments of the

5 eighth group of compounds of formula IXA, R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocycl ring containing at least one nitrogen heteroatom in addition to the nitrogen atom to which R¹ and R² are both bound. In still other embodiments, R¹ and R², together with the nitrogen to which they are bound,

10 form a substituted or unsubstituted heterocycl ring containing at least one oxygen heteroatom. Representative examples of some of the above-described heterocycl embodiments include those for which R¹ and R², together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino,

15 or azepino group. Other embodiments of the eighth group of compounds of formula IXA include those in which R¹ and R², together with the nitrogen to which they are bound, form a substituted piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

In the eighth group of compounds of formula IXA, R³ is selected

20 from the group consisting of H, substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. In one embodiment of the eighth group of compounds of formula IXA, R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, polycyclic cycloalkyl,

25 alkenyl, alkyl, and aryl groups. In other embodiments of the eighth group of compounds of formula IXA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-

30 alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-

diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamanyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups. In other embodiments of the eighth group of compounds of formula IXA, R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohexenyl, 3,3,5-trimethylcyclohexyl, 4-t-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, and 3-methylcycloheptyl groups.

In the eighth group of compounds of formula IXA, R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocycl groups, arylalkyl groups, and heteroarylalkyl groups. In various embodiments of the eighth group of compounds of formula IXA, R⁴ is H.

Another aspect of the invention provides a composition comprising at least one of the compounds represented by the above-listed formulas and a pharmaceutically acceptable carrier.

Another aspect of the invention provides a method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, at least one of the compounds represented by the above-listed formulas. The method may be used to treat diseases and complications

5 arising from diseases which include obesity or type II diabetes. Additionally, the method may be used to treat erectile dysfunction, polycystic ovary disease, and Syndrome X.

The compounds of the invention may generally be assembled through peptide couplings. The reagents and conditions employed in these

10 couplings to form amide bonds are familiar to one of skill in the art. Examples of these coupling conditions can also be found in the review article "Chemical Synthesis of Natural Product Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into Peptides" (Humphrey, J. M.; Chamberlin, A. R.; *Chem. Rev.* 1997, 97, p 2243-2256).


15 One aspect of the invention involves coupling three building blocks: an amino subunit, a central amino acid moiety, and an acyl subunit. The amino subunit is first coupled with the central amino acid moiety containing a nitrogen protecting group. Various common nitrogen protecting groups, such as those listed in "Protective Groups in Organic Synthesis 2nd

20 ed." (Greene, T. W.; Wuts, P. G. M; John Wiley & Sons, Inc.; New York: 1991), may be useful in increasing the efficiency of the coupling reaction with respect to solubility, yield, and chemical and optical purity. After removing the protecting group following coupling, the exposed nitrogen is then coupled with the acyl subunit. Additional functional group or protecting group

25 manipulations may also be required either before or after the coupling steps to generate certain compounds of the invention. Further examples of starting materials for the amino, central amino acid, and acyl subunits and their preparations may be found in WO 00/74679, WO 99/64002, WO 01/70337, and WO 01/70708 which are hereby incorporated by reference. The above-

30 described process can be summarized in the following synthesis scheme:


-75-



Various compounds of the invention may contain a guanidinoaryl moiety. This functionality may generally be prepared as described in U.S. Provisional Patent Application Nos. 60/230,565 and 60/245,579 and in U.S. Patent Application No. 09/945,384, which are herein 5 incorporated by reference.

The amino subunit starting materials may also include guanidinoarylamines or aryl amines containing a handle for introducing guanidino substituents after amide bond coupling. For example, azidoarylamines ($J = N_3$ in scheme below) may be used as the coupling 10 precursors. After the remaining subunits are assembled, the azide may be sequentially treated with a reducing agent, an isocyanate, and an amine to give the desired guanidino substituent. Alternatively a monoprotected aryl diamine ($J = NHPG'$) may also be used. The guanidino unit may be attached by reacting the deprotected aryl amino moiety sequentially with thiophosgene, 15 a first amine, and finally a second amine. The above-described process can be summarized in the following synthesis scheme:

-76-




The starting materials for the central amino acid moiety may also be obtained from commercial sources such as Bachem (King of Prussia, PA) or may be prepared following known methods for the synthesis of unnatural amino acids. Representative examples of these methods may be


5 found in the following reviews and articles: "Highly Practical Methodology for the synthesis of D- and L- α -Amino Acids, *N*-Protected α -Amino Acids, and *N*-Methyl- α -amino acids" (Myers, A.G.; Gleason, J. L.; Yoon, T.; Kung, D. W. J. Am. Chem. Soc, 1997, 119, 656-673), "Recent Developments in the

10 Stereoselective Synthesis of α -amino acids" (R. Duthaler, Tetrahedron, 1994, 50, p.1539-1650), and "Organic Chemistry Series Volume 7: Synthesis of Optically Active α -Amino Acids (Williams, R. M.; Permagon Press: Oxford, 1989).

The acyl subunit may also include a guanidinoaryl moiety. This functionality may be introduced by using azido-substituted or monoamine 15 protected benzoic acids as the starting materials in the appropriate coupling step (see scheme below). The azide or protected amine may then be converted to a guanidino group in the same manner as described above.




Other examples of starting materials for the acyl subunits include the bicyclic acids below prepared and described in WO 00/74679 and WO 99/64002.




In one aspect of the instant invention the R substituent is a

5 guanidino group or a latent guanidino group masked as a protected amine or as an azide. This temporary functionality may later be converted to a guanidino group in the same manner as described above. An example is shown in the scheme below.

Route 1:



Route 2:



The instant invention also provides for compositions which may

10 be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders. Examples of such disorders include, but are not limited to obesity, erectile disorders, cardiovascular disorders, neuronal 15 injuries or disorders, inflammation, fever, cognitive disorders, sexual behavior disorders. A therapeutically effective dose further refers to that amount of one

or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder. The pharmaceutical compositions of the instant invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, 5 emulsifying or levigating processes, among others. The compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral administration, by intranasal administration, by 10 transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The compound or compounds of the instant invention can also be administered in a local rather than a systemic fashion, such as injection as a sustained 15 release formulation. The following dosage forms are given by way of example and should not be construed as limiting the instant invention.

For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by 20 mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient such as a starch or other additive. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, 25 gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone. Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic 30 acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, a thickeners, buffers, a sweeteners, flavoring

agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.

Liquid dosage forms for oral administration may be in the form of

5 pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these. Pharmaceutically suitable surfactants,

10 suspending agents, emulsifying agents, may be added for oral or parenteral administration.

As noted above, suspensions may include oils. Such oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension preparation may also contain esters of fatty acids

15 such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides. Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may

20 also be used in suspension formulations.

For intranasal administration (e.g., to deliver compounds to the brain), or administration by inhalation (e.g., to deliver compounds through the lungs), the pharmaceutical formulations may be a solution, a spray, a dry powder, or aerosol containing any appropriate solvents and optionally other

25 compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. Examples of intranasal formulations and methods of administration can be found in WO 01/41782, WO 00/33813, WO 91/97947, U.S. Patent No. 6,180,603, and U.S. Patent No. 5,624,898. A propellant for

30 an aerosol formulation may include compressed air, nitrogen, carbon dioxide,

or a hydrocarbon based low boiling solvent. The compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.

Injectable dosage forms generally include aqueous suspensions
5 or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may
10 be employed as solvents or suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.

For injection, the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above.
15 Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection
20 such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.

For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal
25 suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the
30 body, such as in the rectum. Oils may also be employed in the preparation of

formulations of the soft gelatin type and suppositories. Water, saline, aqueous dextrose and related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, 5 hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.

Besides those representative dosage forms described above, pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such 10 excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.

The formulations of the invention may be designed for to be short-acting, fast-releasing, long-acting, and sustained-releasing as described 15 below. Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release.

The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage 20 and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.

25 A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms. Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage

forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention.

A therapeutically effective dose may vary depending upon the route of administration and dosage form. The preferred compound or compounds of

5 the instant invention is a formulation that exhibits a high therapeutic index.

The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD50 and ED50. The LD50 is the dose lethal to 50% of the population and the ED50 is the dose therapeutically effective in 50% of the population. The LD50 and ED50 are

10 determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.

The present invention also provides methods of enhancing MC4-R activity in a human or non-human animal. The method comprises administering an effective amount of a compound, or composition, of the 15 instant invention to said mammal or non-human animal. Effective amounts of the compounds of the instant invention include those amounts that activate MC4-R which are detectable, for example, by an assay described below, or any other assay known by those skilled in the art that detect signal transduction, in a biochemical pathway, through activation of G-protein

20 coupled receptors, for example, by measuring an elevated cAMP level as compared to a control model. Accordingly, "activating" means the ability of a compound to initiate a detectable signal. Effective amounts may also include those amounts which alleviate symptoms of a MC4-R disorder treatable by activating MC4-R.

25 An MC4-R disorder, or MC4-R-mediated disease, which may be treated by those methods provided, include any biological disorder or disease in which MC4-R is implicated, or which inhibition of MC4-R potentiates a biochemical pathway that is defective in the disorder or disease state.

Examples of such diseases are obesity, erectile disorders, cardiovascular 30 disorders, neuronal injuries or disorders, inflammation, fever, cognitive

disorders, type II diabetes, polycystic ovary disease, Syndrome X, complications from obesity and diabetes, and sexual behavior disorders. In a preferred embodiment, the instant invention provides compounds, compositions, and methods effective for reducing energy intake and body weight; reducing serum insulin and glucose levels; alleviating insulin resistance; and reducing serum levels of free fatty acids. Accordingly, the instant invention is particularly effective in treating those disorders or diseases associated with obesity or type II diabetes.

"Treating" within the context of the instant invention, therefore,

10 means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder. For example, within the context of obesity, successful treatment may include an alleviation of symptoms or halting the progression of the disease, as measured by reduction in body

15 weight, or a reduction in amount of food or energy intake. In this same vein, successful treatment of type I or type II diabetes may include an alleviation of symptoms or halting the progression of the disease, as measured by a decrease in serum glucose or insulin levels in, for example, hyperinsulinemic or hyperglycemic patients.

20 EC₅₀ values of test compounds may be determined by treating cells expressing MC4-R with test compound and lysing the cells and measuring intercellular cAMP concentration with an Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. The compounds of the invention having the various formula IA through IXA are tested and display

25 -log EC₅₀ values above about 3.

In vivo studies are conducted to observe the effect of MCR-4 agonists on energy intake, body weight, hyperinsulinemia, and glucose levels. All studies are conducted with male 9-10 week old ob/ob mice which display early onset of obesity, insulin resistance and diabetes due to leptin deficiency.

30 Mice are acclimated in the facility for 1 week before studies and are caged

individually. Vehicle-treated (control) and drug treated mice studies are always run in parallel. In multi-day studies, mice (8-15 per group) are monitored for baseline body weight, fasting levels of glucose, insulin, blood lipids and energy expenditure and then injected twice daily (9 a.m. and 5 p.m.)

5 with 3 mg/kg of a MC4-R agonist of the present invention for 4 weeks. Body weight as well as food and water intake are monitored daily. Animals are fasted overnight for measurements of fasting levels of glucose, insulin, and lipids once a week until the end of the study. Energy expenditure (resting metabolic rate, i.e., O₂ consumption and CO₂ production) are monitored in air

10 tight chambers at the end of the study on fed animals. O₂ consumption and CO₂ production are measured using Oxymax systems (Columbus Instruments). Oral glucose tolerance test (OGTT – a routine test for diabetes and glucose intolerance) is performed on overnight fasted mice at the end of the study. Blood glucose and oral glucose tolerance are measured using a

15 glucose monitor (Onetouch sold by Lifescan). Free fatty acids are measured using an non-esterified free fatty acids enzymatic assay (Waco Chemicals). Serum Insulin levels are measured by immunoassay (Alpco).

The effect of the compounds of the present invention on food intake is determined by measuring grams/mouse/day throughout a 4 week

20 study. Food is monitored every morning. Cumulative food intake represents the total amount of grams the mice consume during the study. A significant reduction in food intake is demonstrated in those mice treated IP with the compounds of the present invention.

The effect of the compounds of the present invention on body weight is determined by measuring grams/mouse throughout a 4 week study.

25 Mice are weighed every morning. A significant body weight reduction is demonstrated in those mice treated IP with the compounds of the present invention.

The effect of the compounds of the present invention on blood glucose levels is determined by measuring blood glucose levels as

30

represented as mg of glucose/dL of blood. Mice are fasted overnight and glucose levels are measured the following morning. Vehicle treated mice show an increase in blood glucose consistent with the rapid progression of diabetes in this mouse strain whereas, diabetes is slowed down considerably

5 in drug treated mice. A significant reduction in fasting glucose levels is demonstrated in those mice treated IP with the compounds of this invention.

The effect of the compounds of the present invention on glucose levels during oral glucose tolerance test (OGTT) is determined by measuring blood glucose in overnight fasted mice. Blood glucose is represented as mg

10 of glucose/dL of blood. Glucose levels are measured the following morning. Orally administered glucose quickly elevates blood glucose, similar to a meal, and the response to this exogenous glucose gives a measure of how well the body regulated glucose homeostasis. Vehicle treated mice show an elevated response to glucose consistent with their diabetic state, whereas drug treated

15 mice show a very much improved glucose disposal.

The effect of the compounds of the present invention on free fatty acid (FFA) levels is determined by measuring mmoles of FFA/L of serum. Mice are fasted overnight and free fatty acid levels are measured the following morning. Vehicle treated mice show elevated levels of FFA throughout the

20 study consistent with their obese state, whereas the drug treated mice diabetes show a dramatic decrease.

The effect of the compounds of the present invention on serum insulin levels is determined by measuring serum insulin levels one hour after single IP dosing of 1 and 3 mg/kg in overnight fasted ob/ob mice. Serum

25 insulin levels are represented as ng of insulin/mL of serum. Drug treated mice show a dose dependent decrease relative to vehicle.

It is understood that the invention is not limited to the embodiments specifically set forth herein for illustration, but embraces all such


-86-

forms thereof as would be understood by one of skill in the art and come within the scope of the following claims.

CLAIMS

What is claimed is:

1. A compound of formula IA




3. wherein

4. V is selected from a carbon atom or is absent from the
 5. ring such that the carbon atom bonded to R¹⁶ is bonded to the carbon atom
 6. bonded to R¹⁹ forming a 5-membered ring;

7. Q, W, X, Y, and Z are independently selected from the
 8. group consisting of carbon atoms and nitrogen atoms;

9. R¹, R², R³, R⁴, and R⁵ may be the same or different, and
 10. are each independently selected from the group consisting of H, Cl, I, F, Br,
 11. OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino,
 12. alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino,
 13. heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
 14. cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl,
 15. heteroarylaminocarbonyl groups, and groups of formula IIA or IIB;



11A

11B

16 wherein R^1 may be absent if W is a nitrogen atom;
17 wherein R^2 may be absent if X is a nitrogen atom;
18 wherein R^3 may be absent if Z is a nitrogen atom;
19 wherein R^4 may be absent if Y is a nitrogen atom;
20 wherein R^5 may be absent if Q is a nitrogen atom;
21 wherein one of R^1 , R^2 , R^3 , R^4 , or R^5 is a group having the
22 formula IIA or IIB;
23 R^1 is selected from the group consisting of H, and
24 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
25 heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
26 R^2 is selected from the group consisting of substituted
27 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
28 heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
29 or R^1 and R^2 , together with the nitrogen to which they are
30 bound, form a substituted or unsubstituted heterocycl or heteroaryl group;
31 R^3 is selected from the group consisting of H, substituted
32 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,
33 heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
34 groups;

35 R⁴ is selected from the group consisting of H, and
36 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
37 heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
38 groups, arylalkyl groups, and heteroarylalkyl groups;

39 R⁶ is selected from the group consisting of H, substituted
40 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
41 groups, substituted and unsubstituted aryl groups, substituted and
42 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
43 groups, substituted and unsubstituted alkenyl groups, substituted and
44 unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups,
45 substituted and unsubstituted heteroarylalkyl groups, substituted and
46 unsubstituted heterocyclalkyl groups, substituted and unsubstituted
47 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups;

48 R⁷ is selected from the group consisting of H, substituted
49 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
50 groups, and substituted and unsubstituted aryl groups;

51 R⁸ is selected from the group consisting of H, substituted
52 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
53 groups, substituted and unsubstituted aryl groups, substituted and
54 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
55 groups, substituted and unsubstituted alkenyl groups, substituted and
56 unsubstituted arylalkyl groups including arylalkyl groups substituted with
57 groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl
58 groups including heteroarylalkyl groups substituted with groups of formula IIA
59 or IIB, substituted and unsubstituted heterocyclalkyl groups, substituted and
60 unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
61 aminoalkyl groups;

62 R⁹ is selected from the group consisting H, substituted
63 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl

-90-

64 groups, substituted and unsubstituted aryl groups, substituted and
65 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
66 groups, substituted and unsubstituted alkenyl groups, substituted and
67 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
68 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
69 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
70 aminoalkyl groups;

71 R¹⁰ is selected from the group consisting of H, substituted
72 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
73 groups, substituted and unsubstituted aryl groups, substituted and
74 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
75 groups, substituted and unsubstituted alkenyl groups, substituted and
76 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
77 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
78 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
79 aminoalkyl groups;

80 R¹¹, R¹², R¹³, R¹⁶, R¹⁷, and R¹⁸ are selected from the
81 group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and
82 unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups,
83 substituted and unsubstituted alkylcarbonylalkyl groups, substituted and
84 unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups,
85 substituted and unsubstituted alkyl groups, substituted and unsubstituted
86 cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted
87 and unsubstituted heteroarylalkyl groups, substituted and unsubstituted
88 heterocyclalkyl groups, substituted and unsubstituted -NH₂ groups,
89 substituted and unsubstituted N(H)(alkyl) groups, substituted and
90 unsubstituted -NH(aryl) groups, substituted and unsubstituted -
91 NH(heterocycl) groups, substituted and unsubstituted -N(alkyl)(aryl) groups,
92 substituted and unsubstituted -N(alkyl)(heterocycl) groups, substituted and
93 unsubstituted -N(aryl)(heterocycl) groups, substituted and unsubstituted -

94 N(alkyl)₂ groups, substituted and unsubstituted -N(aryl)₂ groups, substituted
95 and unsubstituted -N(heterocyclyl)₂ groups, -C(=O)-OH groups, substituted
96 and unsubstituted -C(=O)-O(alkyl) groups; substituted and unsubstituted
97 amide groups, substituted and unsubstituted sulfone groups, and substituted
98 and unsubstituted sulfonamide groups;

99 wherein R¹³ and R¹⁶ together can represent a double
100 bond between the carbon atoms bonded to R¹³ and R¹⁶;

101 wherein R¹⁷ and R¹⁸ are absent if V is absent;

102 R¹⁴ and R¹⁵ are selected from the group consisting of H,
103 and substituted and unsubstituted alkyl groups;

104 or R¹⁴ and R¹⁵ together with the two carbon atoms to
105 which they are bound form a substituted or unsubstituted, saturated or
106 unsaturated, carbocyclic or heterocyclic ring comprising 5, 6, or 7 members;

107 R¹⁹ is selected from the group consisting of H, substituted
108 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
109 groups, and substituted and unsubstituted aryl groups; and

110 prodrugs thereof, pharmaceutically acceptable salts
111 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
112 thereof, and solvates thereof.

1 2. A compound of claim 1, wherein one or more of R¹⁹, R⁶,
2 R⁹, R¹⁰, R⁷, and R⁴ is H.

1 3. A compound of claim 1, wherein R⁸ is selected from the
2 group consisting of substituted and unsubstituted arylalkyl groups, and
3 substituted and unsubstituted heteroarylalkyl groups.

1 4. A compound of claim 1, wherein R³ is selected from the
 2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
 3 cycloalkyl, alkenyl, alkyl, and aryl groups.


1 5. A compound of claim 1, wherein R¹ is H, and R² is
 2 selected from the group consisting of substituted and unsubstituted alkyl,
 3 arylalkyl, and heteroarylalkyl groups.

1 6. A compound of claim 1, wherein R¹ and R², together with
 2 the nitrogen to which they are bound, form a substituted or unsubstituted
 3 heterocyclic group.

1 7. A compound of claim 1, wherein R¹⁴ and R¹⁵ together
 2 with the two carbon atoms to which they are bound form a substituted or
 3 unsubstituted carbocyclic ring comprising 6 members.

1 8. A compound of claim 1, wherein Q is a carbon atom and
 2 R⁵ is a group of formula IIA or IIB.


1 9. A compound of formula IIIA:



IIIA

2 wherein

3 Q, W, X, Y, and Z are independently selected from the
 4 group consisting of carbon atoms and nitrogen atoms;



12 wherein R^1 may be absent if W is a nitrogen atom;

13 wherein R^2 may be absent if X is a nitrogen atom;

14 wherein R^3 may be absent if Z is a nitrogen atom;

15 wherein R^4 may be absent if Y is a nitrogen atom;

16 wherein R^5 may be absent if Q is a nitrogen atom;

17 wherein one of R^1 , R^2 , R^3 , R^4 , or R^5 is a group having the
18 formula IIA or IIB;

19 R^1 is selected from the group consisting of H, and

20 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
21 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

22 R^2 is selected from the group consisting of substituted
23 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
24 heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

25 or R^1 and R^2 , together with the nitrogen to which they are
26 bound, form a substituted or unsubstituted heterocycl or heteroaryl group;

27 R^{3'} is selected from the group consisting of H and
28 substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl,
29 heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and
30 cycloalkylalkyl groups;

31 R⁴ is selected from the group consisting of H, and
32 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
33 heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
34 groups, arylalkyl groups, and heteroarylalkyl groups;

44 R⁷ is selected from the group consisting of H, substituted
45 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
46 groups, and substituted and unsubstituted aryl groups:

54 groups including heteroarylalkyl groups substituted with groups of formula IIA
55 or IIB, substituted and unsubstituted heterocyclalkyl groups, substituted and
56 unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
57 aminoalkyl groups;

58 R^9 , R^{10} , R^{11} , R^{12} , R^{15} , R^{16} , R^{17} , and R^{18} are selected from
59 the group consisting of H, Cl, F, Br, I, OH, -CN, -NO₂ substituted and
60 unsubstituted alkoxy groups, and substituted and unsubstituted alkyl groups;

61 R^{13} and R^{14} are independently selected from the group
62 consisting of H, substituted and unsubstituted alkyl groups, substituted and
63 unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups,
64 substituted and unsubstituted arylalkyl groups, substituted and unsubstituted
65 heterocyclalkyl groups, substituted and unsubstituted -C(=O)-O(alkyl)
66 groups, substituted and unsubstituted -C(=O)-O(aryl) groups, -C(=O)-OH
67 groups, -C(=O)-NH₂ groups, substituted and unsubstituted -C(=O)-N(H)(alkyl)
68 groups, substituted and unsubstituted -C(=O)-N(alkyl)₂ groups, substituted
69 and unsubstituted -C(=O)-N(H)(aryl) groups, substituted and unsubstituted
70 -C(=O)-N(aryl)(alkyl) groups, substituted and unsubstituted -C(=O)-N(aryl)₂
71 groups, substituted and unsubstituted -C(=O)-N(H)(heterocyclyl) groups,
72 substituted and unsubstituted -C(=O)-N(alkyl)(heterocyclyl) groups,
73 substituted and unsubstituted -C(=O)-N(aryl)(heterocyclyl) groups, substituted
74 and unsubstituted -C(=O)-N(heterocyclyl)₂ groups; and substituted an
75 unsubstituted alkylsulfonylalkyl groups;

76 or R^{13} and R^{14} may join together with the carbon atom to
77 which they are bound to form a substituted or unsubstituted carbocyclic or
78 heterocyclic ring; and

79 prodrugs thereof, pharmaceutically acceptable salts
80 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
81 thereof, and solvates thereof.

1 10. A compound of claim 9, wherein one or more of R⁴, R⁶,
2 and R⁷ is H.

1 11. A compound of claim 9, wherein R⁸ is selected from the
2 group consisting of substituted and unsubstituted arylalkyl groups, and
3 substituted and unsubstituted heteroarylalkyl groups.

1 12. A compound of claim 9, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.

1 13. A compound of claim 9, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.


1 14. A compound of claim 9, wherein R¹ and R², together with
2 the nitrogen to which they are bound form, a substituted or unsubstituted
3 heterocycl group.

1 15. A compound of claim 9, wherein R¹³ and R¹⁴, together
2 with the carbon atom to which they are bound, form a substituted or
3 unsubstituted carbocyclic or heterocyclic ring.

1 16. A compound of claim 9, wherein Q is a carbon atom and
2 R⁵ is a group of formula IIA or IIB.

1


17. A compound of claim 9 having formula IIIB:



2 wherein the dotted lines in the 6-membered carbocyclic
3 ring indicate that the 6-membered ring is a substituted or unsubstituted
4 cyclohexyl or benzene ring; and

5 further wherein A is independently selected from the
6 group consisting of a CH₂ group, a C(=O) group, a NH group, a substituted or
7 unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-
8 NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group,
9 a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and
10 unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl
11 groups.

18. A compound of formula IVA:



2

wherein

3 V is selected from a carbon atom or is absent from the
4 ring such that the carbon atom bonded to R^{28} is bonded to the carbon atom
5 bonded to R^{15} forming a 5-membered ring.

6 W, X, Y, and Z are independently selected from the group
7 consisting of carbon atoms and nitrogen atoms;

27 wherein or R^5 and R^6 may join together with the carbon to
28 which they are bound form a substituted or unsubstituted carbocyclic or
29 heterocyclic ring;

30 R¹¹ is selected from the group consisting of H, substituted
31 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
32 groups, and substituted and unsubstituted aryl groups;


44 R¹³ and R¹⁴ are independently selected from the group
45 consisting of H, substituted and unsubstituted alkyl groups, substituted and
46 unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups,
47 substituted and unsubstituted heterocyclyl groups, substituted and
48 unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups,
49 substituted and unsubstituted arylalkyl groups, substituted and unsubstituted
50 heteroarylalkyl groups, substituted and unsubstituted heterocyclalkyl groups,
51 substituted and unsubstituted cycloalkylalkyl groups, and substituted and
52 unsubstituted aminoalkyl groups;

53 R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected
54 from H, substituted and unsubstituted alkyl groups, substituted and
55 unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl
56 groups:

57 wherein R^{16} and R^{17} are absent if V is absent:

-100-

58 R^{20} , R^{22} , R^{24} , and, R^{26} are independently selected from
 59 the group consisting of H, substituted and unsubstituted alkyl groups, and
 60 groups having the formula IIA or IIB;



61 wherein R^{20} may be absent if W is a nitrogen atom;
 62 wherein R^{22} may be absent if X is a nitrogen atom;
 63 wherein R^{24} may be absent if Y is a nitrogen atom;
 64 wherein R^{26} may be absent if Z is a nitrogen atom;
 65 wherein one of R^{20} , R^{22} , R^{24} or R^{26} is a group having the
 66 formula IIA or IIB;

67 R^1' is selected from the group consisting of H, and
 68 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 69 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

70 R^2' is selected from the group consisting of substituted
 71 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
 72 heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

73 or R^1' and R^2' , together with the nitrogen to which they are
 74 bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group;

75 R^3' is selected from the group consisting of H, substituted
 76 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,

-101-

77 heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
78 groups;

79 R⁴ is selected from the group consisting of H, and
80 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
81 heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
82 groups, arylalkyl groups, and heteroarylalkyl groups; and

91 R²⁸ and R²⁹ are independently selected from the group
92 consisting of H, and substituted and unsubstituted alkyl groups:

93 wherein R^{28} and R^{29} together can represent a double
94 bond between the carbon atoms bonded to R^{28} and R^{29} , and

95 prodrugs thereof, pharmaceutically acceptable salts
96 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
97 thereof, and solvates thereof.

1 19. A compound of claim 18, wherein one or more of $R^{4'}$, R^{11} ,
2 R^{13} , R^{14} , and R^{15} is H.

1 20. A compound of claim 18, wherein R¹² is selected from the
2 group consisting of substituted and unsubstituted arylalkyl groups, and
3 substituted and unsubstituted heteroarylalkyl groups.

1 21. A compound of claim 18, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.


1 22. A compound of claim 18, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.

1 23. A compound of claim 18, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted
3 dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-
4 methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and
5 thiophene groups.

1 24. A compound of claim 18, wherein R¹ and R², together
2 with the nitrogen to which they are bound, form a substituted or unsubstituted
3 heterocyclyl group.


1 25. A compound of claim 18, wherein R⁵ and R⁶, together
2 with carbon atom to which they are bound, form a substituted or unsubstituted
3 carbocyclic or heterocyclic ring.

1 26. A compound of claim 18 having the formula IVB:



2 wherein the dotted lines in the 6-membered carbocyclic
3 ring indicate that the 6-membered ring is a substituted or unsubstituted
4 cyclohexyl or benzene ring; and
5 further wherein A is independently selected from the
6 group consisting of a CH₂ group, a C(=O) group, a NH group, a substituted or
7 unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-
8 NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group,
9 a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and
10 unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl
11 groups.

1 27. A compound of formula VA:




VA

2 wherein

5 Q, W, X, Y, and Z are independently selected from the
6 group consisting of carbon atoms and nitrogen atoms;

-104-

12 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl,
 13 heteroarylaminocarbonyl groups, and groups of formula IIA or IIB;



14 wherein R¹ may be absent if W is a nitrogen atom;
 wherein R² may be absent if X is a nitrogen atom;
 15 wherein R³ may be absent if Z is a nitrogen atom;
 wherein R⁴ may be absent if Y is a nitrogen atom;
 17 wherein R⁵ may be absent if Q is a nitrogen atom;
 18 wherein one of R¹, R², R³, R⁴, or R⁵ is a group having the
 19 formula IIA or IIB;
 20 R^{1'} is selected from the group consisting of H, and
 21 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 22 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
 23 R^{2'} is selected from the group consisting of substituted
 24 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
 25 heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
 26 or R^{1'} and R^{2'}, together with the nitrogen to which they are
 27 bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group;
 28 R^{3'} is selected from the group consisting of H, substituted
 29 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,

30 heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
31 groups;

32 R⁴ is selected from the group consisting of H, and
33 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
34 heterocyclylalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
35 groups, arylalkyl groups, and heteroarylalkyl groups;

36 R⁶ is selected from the group consisting of H, substituted
37 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
38 groups, substituted and unsubstituted aryl groups, substituted and
39 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
40 groups, substituted and unsubstituted alkenyl groups, substituted and
41 unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups,
42 substituted and unsubstituted heteroarylalkyl groups, substituted and
43 unsubstituted heterocyclylalkyl groups, substituted and unsubstituted
44 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups;

45 R⁷ is selected from the group consisting of H, substituted
46 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
47 groups, and substituted and unsubstituted aryl groups;

48 R⁸ is selected from the group consisting of H, substituted
49 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
50 groups, substituted and unsubstituted aryl groups, substituted and
51 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
52 groups, substituted and unsubstituted alkenyl groups, substituted and
53 unsubstituted arylalkyl groups including arylalkyl groups substituted with
54 groups of formula IIA or IIB, substituted and unsubstituted heteroarylalkyl
55 groups including heteroarylalkyl groups substituted with groups of formula IIA
56 or IIB, substituted and unsubstituted heterocyclylalkyl groups, substituted and
57 unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
58 aminoalkyl groups;

59 R⁹ is selected from the group consisting H, substituted
60 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
61 groups, substituted and unsubstituted aryl groups, substituted and
62 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
63 groups, substituted and unsubstituted alkenyl groups, substituted and
64 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
65 groups, substituted and unsubstituted heterocyclylalkyl groups, substituted
66 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
67 aminoalkyl groups;

68 R¹⁰ is selected from the group consisting of H, substituted
69 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
70 groups, substituted and unsubstituted aryl groups, substituted and
71 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
72 groups, substituted and unsubstituted alkenyl groups, substituted and
73 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
74 groups, substituted and unsubstituted heterocyclylalkyl groups, substituted
75 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
76 aminoalkyl groups;

89 substituted and unsubstituted $-N(alkyl)(heterocycl)$ groups, substituted and
90 unsubstituted $-N(aryl)(heterocycl)$ groups, substituted and unsubstituted $-$
91 $N(alkyl)_2$ groups, substituted and unsubstituted $-N(aryl)_2$ groups, substituted
92 and unsubstituted $-N(heterocycl)_2$ groups, $-C(=O)-OH$ groups, substituted
93 and unsubstituted $-C(=O)-O(alkyl)$ groups; substituted and unsubstituted
94 amide groups, substituted and unsubstituted sulfone groups, and substituted
95 and unsubstituted sulfonamide groups;

96 R^{15} is selected from the group consisting of H, substituted
97 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
98 groups, substituted and unsubstituted aryl groups, substituted and
99 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
100 groups, substituted and unsubstituted alkenyl groups, substituted and
101 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
102 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
103 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
104 aminoalkyl groups;

105 or R^{12} and R^{14} together with the carbon atoms to which
106 they are bound, may form a substituted or unsubstituted, saturated or
107 unsaturated carbocyclic or heterocyclic ring comprising 5 or 6 members;

108 or R^{14} and R^{15} together with the atoms to which they are
109 bound, may form a substituted or unsubstituted, saturated or unsaturated
110 heterocyclic ring comprising 5 or 6 members;

111 R^{18} is selected from the group consisting of H, substituted
112 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
113 groups, and substituted and unsubstituted aryl groups; and

114 prodrugs thereof, pharmaceutically acceptable salts
115 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
116 thereof, and solvates thereof.

1 28. A compound of claim 27, wherein one or more of R¹⁸, R⁶,
2 R⁹, R¹⁰, R⁷, and R⁴ is H.

1 29. A compound of claim 27, wherein R⁸ is selected from the
2 group consisting of substituted and unsubstituted arylalkyl groups, and
3 substituted and unsubstituted heteroarylalkyl groups.

1 30. A compound of claim 27, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.

1 31. A compound of claim 27, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.


1 32. A compound of claim 27, wherein R¹ and R², together
2 with the nitrogen to which they are bound, form a substituted or unsubstituted
3 heterocyclyl group.

1 33. A compound of claim 27, wherein T is an NR¹⁵ group and
2 R¹⁴ and R¹⁵ together with the atoms to which they are bound form a
3 substituted or unsubstituted heterocyclic ring comprising 6 members.

1 34. A compound of claim 27, wherein Q is a carbon atom and
2 R⁵ is a group of formula IIA or IIB.

1

35. A compound of formula VIA:



wherein

2 V is selected from a carbon atom or is absent from the
3 ring such that the carbon atom bonded to R¹⁵ is bonded to the carbon atom
4 bonded to R¹⁸ forming a 5-membered ring;

5 Q', W', X', Y', and Z' are independently selected from the
6 group consisting of carbon atoms and nitrogen atoms;

19 unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups,
20 substituted and unsubstituted heteroarylalkyl groups, substituted and
21 unsubstituted heterocyclalkyl groups, substituted and unsubstituted
22 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups;

23 R^7 is selected from the group consisting of H, substituted
24 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
25 groups, and substituted and unsubstituted aryl groups;

26 R^8 is selected from the group consisting H, substituted
27 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
28 groups, substituted and unsubstituted aryl groups, substituted and
29 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
30 groups, substituted and unsubstituted alkenyl groups, substituted and
31 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
32 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
33 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
34 aminoalkyl groups;

35 R^9 is selected from the group consisting of H, substituted
36 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
37 groups, substituted and unsubstituted aryl groups, substituted and
38 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
39 groups, substituted and unsubstituted alkenyl groups, substituted and
40 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
41 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
42 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
43 aminoalkyl groups;

44 R^{10} , R^{11} , R^{12} , R^{15} , R^{16} , and R^{17} are selected from the
45 group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and
46 unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups,
47 substituted and unsubstituted alkylcarbonylalkyl groups, substituted and

48 unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups,
49 substituted and unsubstituted alkyl groups, substituted and unsubstituted
50 cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted
51 and unsubstituted heteroarylalkyl groups, substituted and unsubstituted
52 heterocyclalkyl groups, substituted and unsubstituted $-NH_2$ groups,
53 substituted and unsubstituted $N(H)(alkyl)$ groups, substituted and
54 unsubstituted $-NH(aryl)$ groups, substituted and unsubstituted $-$
55 $NH(heterocycl)$ groups, substituted and unsubstituted $-N(alkyl)(aryl)$ groups,
56 substituted and unsubstituted $-N(alkyl)(heterocycl)$ groups, substituted and
57 unsubstituted $-N(aryl)(heterocycl)$ groups, substituted and unsubstituted $-$
58 $N(alkyl)_2$ groups, substituted and unsubstituted $-N(aryl)_2$ groups, substituted
59 and unsubstituted $-N(heterocycl)_2$ groups, $-C(=O)-OH$ groups, substituted
60 and unsubstituted $-C(=O)-O(alkyl)$ groups; substituted and unsubstituted
61 amide groups, substituted and unsubstituted sulfone groups, and substituted
62 and unsubstituted sulfonamide groups;


65 wherein R^{16} and R^{17} are absent if V is absent;

66 R^{13} and R^{14} are selected from the group consisting of H,
67 and substituted and unsubstituted alkyl groups;

68 or R^{13} and R^{14} together with the two carbon atoms to
69 which they are bound form a substituted or unsubstituted, saturated or
70 unsaturated, carbocyclic or heterocyclic ring comprising 5, 6, or 7 members.

74 R¹⁹, R²⁰, R²¹, R²², and R²³ may be the same or different,
75 and are each independently selected from the group consisting of H, Cl, I, F

76 Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino,
 77 alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocycllamino,
 78 heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
 79 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl,
 80 heteroarylaminocarbonyl groups, and groups of formula IIA or IIB;



81 wherein R²² may be absent if W' is a nitrogen atom;
 82 wherein R²³ may be absent if X' is a nitrogen atom;
 83 wherein R¹⁹ may be absent if Z' is a nitrogen atom;
 84 wherein R²⁰ may be absent if Y' is a nitrogen atom;
 85 wherein R²¹ may be absent if Q' is a nitrogen atom;
 86 wherein one of R¹⁹, R²⁰, R²¹, R²², or R²³ is a group having
 87 the formula IIA or IIB;
 88 R^{1'} is selected from the group consisting of H, and
 89 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 90 heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
 91 R^{2'} is selected from the group consisting of substituted
 92 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
 93 heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;
 94 or R^{1'} and R^{2'}, together with the nitrogen to which they are
 95 bound, form a substituted or unsubstituted heterocycl or heteroaryl group;

96 R³ is selected from the group consisting of H, substituted
97 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,
98 heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
99 groups;

104 prodrugs thereof, pharmaceutically acceptable salts
105 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
106 thereof, and solvates thereof.

1 36. A compound of claim 35, wherein one or more of R^4 , R^6 ,
2 R^7 , R^8 , R^9 , and R^{18} is H.

1 37. A compound of claim 35, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.

1 38. A compound of claim 35, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.


1 39. A compound of claim 35, wherein R¹ and R², together
2 with the nitrogen to which they are bound, form a substituted or unsubstituted
3 heterocyclyl group.

1 40. A compound of claim 35, wherein R¹³ and R¹⁴ together
2 with the two carbon atoms to which they are bound form a substituted or
3 unsubstituted carbocyclic ring comprising 6 members.

1 41. A compound of claim 35, wherein Q' is a carbon atom
2 and R²¹ is a group of formula IIA or IIB.

1

42. A compound having the formula VIIA:



2

wherein

3 Q', W', X', Y', and Z' are independently selected from the
4 group consisting of carbon atoms and nitrogen atoms:


12 R⁶ is selected from the group consisting of H, substituted
13 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
14 groups, substituted and unsubstituted aryl groups, substituted and
15 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
16 groups, substituted and unsubstituted alkenyl groups, substituted and
17 unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups,
18 substituted and unsubstituted heteroarylalkyl groups, substituted and
19 unsubstituted heterocyclylalkyl groups, substituted and unsubstituted
20 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups;

21 R⁷ is selected from the group consisting of H, substituted
22 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
23 groups, and substituted and unsubstituted aryl groups:


24 R⁸, R⁹, R¹⁰, R¹¹, R¹⁴, R¹⁵, R¹⁶, and R¹⁷ are selected from
25 the group consisting of H, Cl, F, Br, I, OH, -CN, -NO₂ substituted and
26 unsubstituted alkoxy groups, and substituted and unsubstituted alkyl groups:

42 wherein R^{12} and R^{13} may join together with the carbon to
43 which they are bound form a substituted or unsubstituted carbocyclic or
44 heterocyclic ring including carbocyclic and heterocyclic rings substituted by a
45 group of formula IIA or IIB:

50 heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
 51 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl,
 52 heteroarylaminocarbonyl groups, and groups of formula IIA or IIB;



IIA



IIB

53 wherein R²¹ may be absent if W' is a nitrogen atom;

54 wherein R²² may be absent if X' is a nitrogen atom;

55 wherein R¹⁸ may be absent if Z' is a nitrogen atom;

56 wherein R¹⁹ may be absent if Y' is a nitrogen atom;

57 wherein R²⁰ may be absent if Q' is a nitrogen atom;

58 wherein one of R¹⁸, R¹⁹, R²⁰, R²¹, or R²² is a group having
 59 the formula IIA or IIB;

60 R^{1'} is selected from the group consisting of H, and
 61 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 62 heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

63 R^{2'} is selected from the group consisting of substituted
 64 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
 65 heterocycl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

66 or R^{1'} and R^{2'}, together with the nitrogen to which they are
 67 bound, form a substituted or unsubstituted heterocycl or heteroaryl group;

68 R³ is selected from the group consisting of H and
69 substituted and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl,
70 heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and
71 cycloalkylalkyl groups:

72 R⁴ is selected from the group consisting of H, and
73 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
74 heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
75 groups, arylalkyl groups, and heteroarylalkyl groups; and

76 prodrugs thereof, pharmaceutically acceptable salts
77 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
78 thereof, and solvates thereof.

1 43. A compound of claim 42, wherein one or more of R^4 , R^6 ,
2 and R^7 is H.

1 44. A compound of claim 42, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.

1 45. A compound of claim 42, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.


1 46. A compound of claim 42, wherein R¹ and R², together
2 with the nitrogen to which they are bound form a substituted or unsubstituted
3 heterocyclic group.

1 47. A compound of claim 42, wherein R^{12} and R^{13} , together
2 with the carbon atom to which they are bound, form a substituted or
3 unsubstituted carbocyclic or heterocyclic ring.

1 48. A compound of claim 42, wherein Q' is a carbon atom
2 and R²⁰ is a group of formula IIA or IIB

1

49. A compound of claim 42 having formula VII B:




2

wherein the dotted lines in the 6-membered carbocyclic ring indicate that the 6-membered ring is a substituted or unsubstituted cyclohexyl or benzene ring; and

5 further wherein A is independently selected from the
 6 group consisting of a CH₂ group, a C(=O) group, a NH group, a substituted or
 7 unsubstituted N(alkyl) group, a C(H)(C(=O)-O(alkyl)) group, a C(H)(C(=O)-
 8 NH₂) group, a C(H)(C(=O)-N(H)(alkyl)) group, a C(H)(C(=O)-N(H)(aryl)) group,
 9 a C(H)(C(=O)-N(alkyl)₂) group, a C(H)(C(=O)-N(aryl)₂) group, substituted and
 10 unsubstituted alkoxyalkyl groups, and substituted and unsubstituted arylalkyl
 11 groups.

1

50. A compound of formula VII A:



2 wherein

3 V is selected from a carbon atom or is absent from the
4 ring such that the carbon atom bonded to R^{27} is bonded to the carbon atom
5 bonded to R^{14} forming a 5-membered ring;

6 W, X, Y, and Z are independently selected from the group
7 consisting of carbon atoms and nitrogen atoms:

8 Q', W', X', Y', and Z' are independently selected from the
9 group consisting of carbon atoms and nitrogen atoms:

21 groups, substituted and unsubstituted $-C(=O)-N(alkyl)_2$ groups, substituted
22 and unsubstituted $-C(=O)-N(H)(aryl)$ groups, substituted and unsubstituted
23 $-C(=O)-N(aryl)(alkyl)$ groups, substituted and unsubstituted $-C(=O)-N(aryl)_2$
24 groups, substituted and unsubstituted $-C(=O)-N(H)(heterocyclyl)$ groups,
25 substituted and unsubstituted $-C(=O)-N(alkyl)(heterocyclyl)$ groups,
26 substituted and unsubstituted $-C(=O)-N(aryl)(heterocyclyl)$ groups, substituted
27 and unsubstituted $-C(=O)-N(heterocyclyl)_2$ groups; and substituted and
28 unsubstituted alkylsulfonylalkyl groups;


29 wherein R^5 and R^6 may join together with the carbon to
30 which they are bound form a substituted or unsubstituted carbocyclic or
31 heterocyclic ring including carbocyclic or heterocyclic rings substituted with a
32 group of formula IIA or IIB;

33 R^{11} is selected from the group consisting of H, substituted
34 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
35 groups, and substituted and unsubstituted aryl groups;

36 R^{12} and R^{13} are independently selected from the group
37 consisting of H, substituted and unsubstituted alkyl groups, substituted and
38 unsubstituted cycloalkyl groups, substituted and unsubstituted aryl groups,
39 substituted and unsubstituted heterocyclyl groups, substituted and
40 unsubstituted heteroaryl groups, substituted and unsubstituted alkenyl groups,
41 substituted and unsubstituted arylalkyl groups, substituted and unsubstituted
42 heteroarylalkyl groups, substituted and unsubstituted heterocyclylalkyl groups,
43 substituted and unsubstituted cycloalkylalkyl groups, and substituted and
44 unsubstituted aminoalkyl groups;

45 R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are independently selected
46 from H, substituted and unsubstituted alkyl groups, substituted and
47 unsubstituted cycloalkyl groups, and substituted and unsubstituted aryl
48 groups;

49 wherein R^{15} and R^{16} are absent if V is absent;



IIA

118

73 wherein R^{31} may be absent if Q' is a nitrogen atom';

74 wherein R^{32} may be absent if W' is a nitrogen atom;

75 wherein R^{33} may be absent if X' is a nitrogen atom;

76 wherein R^{30} may be absent if Y' is a nitrogen atom;

77 wherein R^{29} may be absent if Z' is a nitrogen atom;

78 wherein one of R^{29} , R^{30} , R^{31} , R^{32} , and R^{33} is a group

79 having the formula IIA or IIB;

80 R^1 is selected from the group consisting of H, and

81 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,

82 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

83 R^2 is selected from the group consisting of substituted

84 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,

85 heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

86 or R^1 and R^2 , together with the nitrogen to which they are

87 bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group;

88 R^3 is selected from the group consisting of H, substituted

89 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,

90 heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl

91 groups;

92 R⁴ is selected from the group consisting of H, and
93 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl groups,
94 heterocyclalkyl groups, cycloalkylalkyl, aryl, heteroaryl groups, heterocyclyl
95 groups, arylalkyl groups, and heteroarylalkyl groups; and

96 prodrugs thereof, pharmaceutically acceptable salts
97 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
98 thereof, and solvates thereof.

1 51. A compound of claim 50, wherein one or more of $R^{4'}$, R^{11} ,
2 R^{12} , and R^{13} is H.

1 52. A compound of claim 50, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.


1 53. A compound of claim 50, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.

1 54. A compound of claim 50, wherein R¹ and R², together
2 with the nitrogen to which they are bound, form a substituted or unsubstituted
3 heterocycl group.

1 55. A compound of claim 50, wherein R⁵ and R⁶ together with
2 the carbon atom to which they are bound, form a substituted or unsubstituted
3 carbocyclic or heterocyclic ring.


1

56. A compound of claim 50 having formula VIIIB:



1

57. A compound of formula IXA:



2

wherein

3

T is selected from the group consisting of O, S, and NR¹⁴

4 groups;

5

6 group consisting of carbon atoms and nitrogen atoms;

7 R¹, R², R³, R⁴, and R⁵ may be the same or different, and
8 are each independently selected from the group consisting of H, Cl, I, F, Br,
9 OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino,
10 alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino,
11 heteroaryl amino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
12 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl,
13 heteroarylaminocarbonyl groups, and groups of formula IIA or IIB:

14 R⁶ is selected from the group consisting of H, substituted
15 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
16 groups, substituted and unsubstituted aryl groups, substituted and
17 unsubstituted heterocyclyl groups, substituted and unsubstituted heteroaryl
18 groups, substituted and unsubstituted alkenyl groups, substituted and
19 unsubstituted alkynyl groups, substituted and unsubstituted arylalkyl groups,

20 substituted and unsubstituted heteroarylalkyl groups, substituted and
21 unsubstituted heterocyclalkyl groups, substituted and unsubstituted
22 cycloalkylalkyl groups, and substituted and unsubstituted aminoalkyl groups;

23 R^7 is selected from the group consisting of H, substituted
24 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
25 groups, and substituted and unsubstituted aryl groups;

26 R^8 is selected from the group consisting H, substituted
27 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
28 groups, substituted and unsubstituted aryl groups, substituted and
29 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
30 groups, substituted and unsubstituted alkenyl groups, substituted and
31 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
32 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
33 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
34 aminoalkyl groups;

35 R^9 is selected from the group consisting of H, substituted
36 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
37 groups, substituted and unsubstituted aryl groups, substituted and
38 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
39 groups, substituted and unsubstituted alkenyl groups, substituted and
40 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
41 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
42 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
43 aminoalkyl groups;

44 R^{10} , R^{11} , R^{12} , R^{13} , R^{15} , and R^{16} are selected from the
45 group consisting of H, Cl, F, Br, I, -CN, -OH, -NO₂, substituted and
46 unsubstituted aryl, substituted and unsubstituted -C(=O)-alkyl groups,
47 substituted and unsubstituted alkylcarbonylalkyl groups, substituted and
48 unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups,

49 substituted and unsubstituted alkyl groups, substituted and unsubstituted
50 cycloalkyl groups, substituted and unsubstituted arylalkyl groups, substituted
51 and unsubstituted heteroarylalkyl groups, substituted and unsubstituted
52 heterocyclalkyl groups, substituted and unsubstituted $-NH_2$ groups,
53 substituted and unsubstituted $N(H)(alkyl)$ groups, substituted and
54 unsubstituted $-NH(aryl)$ groups, substituted and unsubstituted $-$
55 $NH(heterocycl)$ groups, substituted and unsubstituted $-N(alkyl)(aryl)$ groups,
56 substituted and unsubstituted $-N(alkyl)(heterocycl)$ groups, substituted and
57 unsubstituted $-N(aryl)(heterocycl)$ groups, substituted and unsubstituted $-$
58 $N(alkyl)_2$ groups, substituted and unsubstituted $-N(aryl)_2$ groups, substituted
59 and unsubstituted $-N(heterocycl)_2$ groups, $-C(=O)-OH$ groups, substituted
60 and unsubstituted $-C(=O)-O(alkyl)$ groups; substituted and unsubstituted
61 amide groups, substituted and unsubstituted sulfone groups, and substituted
62 and unsubstituted sulfonamide groups;


63 R^{14} is selected from the group consisting of H, substituted
64 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
65 groups, substituted and unsubstituted aryl groups, substituted and
66 unsubstituted heterocycl groups, substituted and unsubstituted heteroaryl
67 groups, substituted and unsubstituted alkenyl groups, substituted and
68 unsubstituted arylalkyl groups, substituted and unsubstituted heteroarylalkyl
69 groups, substituted and unsubstituted heterocyclalkyl groups, substituted
70 and unsubstituted cycloalkylalkyl groups, and substituted and unsubstituted
71 aminoalkyl groups;

72 or R^{11} and R^{13} together with the carbon atoms to which
73 they are bound, may form a substituted or unsubstituted, saturated or
74 unsaturated carbocyclic or heterocyclic ring comprising 5 or 6 members;

75 or R^{13} and R^{14} together with the atoms to which they are
76 bound, may form a substituted or unsubstituted, saturated or unsaturated
77 heterocyclic ring comprising 5 or 6 members;

78 R¹⁷ is selected from the group consisting of H, substituted
 79 and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl
 80 groups, and substituted and unsubstituted aryl groups;

81 R¹⁸, R¹⁹, R²⁰, R²¹, and R²² may be the same or different,
 82 and are each independently selected from the group consisting of H, Cl, I, F,
 83 Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted aryl, alkoxy, amino,
 84 alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino,
 85 heteroarylarnino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
 86 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl,
 87 heteroarylaminocarbonyl groups, and groups of formula IIA or IIB;



88 wherein R²¹ may be absent if W' is a nitrogen atom;

89 wherein R²² may be absent if X' is a nitrogen atom;

90 wherein R¹⁸ may be absent if Z' is a nitrogen atom;

91 wherein R¹⁹ may be absent if Y' is a nitrogen atom;

92 wherein R²⁰ may be absent if Q' is a nitrogen atom;

93 wherein one of R¹⁸, R¹⁹, R²⁰, R²¹, and R²² is a group
 94 having the formula IIA or IIB;

95 R^{1'} is selected from the group consisting of H, and
 96 substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 97 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

98 R² is selected from the group consisting of substituted
99 and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
100 heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups;

101 or R^1 and R^2 , together with the nitrogen to which they are
102 bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group;

103 R^{3'} is selected from the group consisting of H, substituted
104 and unsubstituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,
105 heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl
106 groups;

111 prodrugs thereof, pharmaceutically acceptable salts
112 thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides
113 thereof, and solvates thereof

1 58. A compound of claim 57, wherein one or more of R^4 , R^6 ,
2 R^7 , R^8 , R^9 , and R^{17} is H.

1 59. A compound of claim 57, wherein R³ is selected from the
2 group consisting of substituted and unsubstituted cycloalkyl, polycyclic
3 cycloalkyl, alkenyl, alkyl, and aryl groups.

1 60. A compound of claim 57, wherein R¹ is H and R² is
2 selected from the group consisting of substituted and unsubstituted alkyl,
3 arylalkyl, and heteroarylalkyl groups.

1 61. A compound of claim 57, wherein R¹ and R², together
2 with the nitrogen to which they are bound, form a substituted or unsubstituted
3 heterocyclic group.

1 62. A compound of claim 57, wherein T is an NR¹⁴ group and
2 R¹³ and R¹⁴, together with the two atoms to which they are bound, form a
3 substituted or unsubstituted heterocyclic ring comprising 6 members.

1 63. A compound of claim 57, wherein Q' is a carbon atom
2 and R²⁰ is a group of formula IIA or IIB.

1 64. A pharmaceutical formulation or medicament, comprising
2 at least one of the compounds of any one of claims 1, 9, 18, 27, 35, 42, 50, or
3 57 and a pharmaceutically acceptable carrier.

1 65. A method of treating an MC4-R mediated disease,
2 comprising administering to a subject in need thereof, at least one of the
3 compounds of any one of claims 1, 9, 18, 27, 35, 42, 50, or 57.

1 66. A method of claim 65, wherein the MC4-R mediated
2 disease is obesity or type II diabetes.